## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-04-28_Virtual Town Hall 53_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/148253/download?attachment
link youtube: https://youtu.be/txFUTJy6wA8
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Webinar on COVID-19 Test Guidance Updates

QA Block 1-1
CLARIFIED QUESTION: Does the pooling and serial testing amendment only apply to RT-PCRs or can other types of nucleic acid amplification tests (NAATs) also fall under this amendment?
CLARIFIED ANSWER: The pooling and serial testing amendment specifically applies to previously authorized molecular RT-PCR SARS-CoV-2 tests that meet all criteria in the amendment. Other NAATs may qualify if they submit an individual supplemental EUA request. Validation approaches outlined in the amendment may be used depending on test technology.
VERBATIM QUESTION: Does the pooling and serial testing amendment only apply to RT-PCRs or can other types of nucleic acid amplification tests (NAATs) also fall under this amendment?
VERBATIM ANSWER: The amendment is specific to previously authorized molecular-based RT-PCR SARS-CoV-2 tests that are - that meet all of the criteria outlined in the amendment. This is based on the experience we've had with SARS-CoV-2 tests over the past year and our experience with data that demonstrates that tests within the scope of the amendment are likely to maintain appropriate performance when they add pooling. Other types of NAATs may be able to add the same indication but we would expect an individual supplemental EUA request to add the same pooled serial screening indications. The validation approaches that are outlined in the appendices of the amendment may be applicable depending on the technology. But you would have to take a look and see whether those validation approaches would work for your test. For example, there are, you know, some of the validation approaches require the use of CT scores and some tests don't return CT scores. So there are two validation options for media pooling. Option 2, I believe it is, does not rely on CT scores so that would likely be the applicable validation option for a test that does not use CT scores.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pooling and serial testing amendment, RT-PCR applicability, Supplemental EUA for NAATs
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: Are the validation approaches outlined in the appendices of the amendment applicable to other types of NAATs depending on the technology?
CLARIFIED ANSWER: The validation approaches in the amendment may apply to other NAATs depending on the technology, but specific tests must assess applicability. Some approaches use CT scores, but Option 2 for media pooling does not, making it suitable for tests without CT scores.
VERBATIM QUESTION: Are the validation approaches outlined in the appendices of the amendment applicable to other types of NAATs depending on the technology?
VERBATIM ANSWER: The validation approaches that are outlined in the appendices of the amendment may be applicable depending on the technology. But you would have to take a look and see whether those validation approaches would work for your test. For example, there are, you know, some of the validation approaches require the use of CT scores and some tests don't return CT scores. So there are two validation options for media pooling. Option 2, I believe it is, does not rely on CT scores so that would likely be the applicable validation option for a test that does not use CT scores.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Validation approaches, NAATs technology, Pooling and serial testing
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What information about prevalence assumptions is provided on the updated EUA serology test performance webpage?
CLARIFIED ANSWER: The FDA updated the EUA serology test performance webpage to include information on the expected predictive value of authorized serology tests based on prevalence assumptions ranging from 5% to 50%, to assist healthcare providers in interpreting antibody test results.
VERBATIM QUESTION: What information about prevalence assumptions is provided on the updated EUA serology test performance webpage?
VERBATIM ANSWER: That page has been updated to provide additional information on the expected predictive value of authorized serology tests that have submitted performance data to provide information for prevalence assumptions ranging from 5% to 50% to potentially help healthcare providers interpret those antibody test results for their patients in their communities.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA serology test performance, Prevalence assumptions, Healthcare provider guidance
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: How should healthcare providers interpret predictive values on serology tests based on new prevalence data?
CLARIFIED ANSWER: The FDA has updated the webpage for EUA-authorized serology test performance with predictive value information, based on prevalence assumptions (5%-50%), to assist healthcare providers in interpreting antibody test results for patients in their communities.
VERBATIM QUESTION: How should healthcare providers interpret predictive values on serology tests based on new prevalence data?
VERBATIM ANSWER: Just a quick update on the web page for EUA authorized serology test performance. If you're on our email list you likely got an email earlier today. That page has been updated to provide additional information on the expected predictive value of authorized serology tests that have submitted performance data to provide information for prevalence assumptions ranging from 5% to 50% to potentially help healthcare providers interpret those antibody test results for their patients in their communities.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serology test performance, predictive value, healthcare interpretation
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What does Condition F in the recent pooling and serial testing amendment entail regarding post-authorization studies?
CLARIFIED ANSWER: Condition F pertains to the screening aspect of the test's indication. Pooling must be validated beforehand and submitted as part of the request. The post-authorization studies emphasize validation with asymptomatic individuals, aligned with the serial screening supplemental template.
VERBATIM QUESTION: What does Condition F in the recent pooling and serial testing amendment entail regarding post-authorization studies?
VERBATIM ANSWER: That commitment or that condition is specific to the screening aspect of the indication. So the pooling aspect we do expect to be validated ahead of time as outlined in the amendment. And those - that validation should be submitted as part of your request to be added to the exhibit. The post-authorization condition lines up with the approach that we outlined in the serial screening supplemental template that we posted last month. March 16th I believe. That provided a path for authorization of screening claims prior to validation with asymptomatic individuals. So under this amendment we've rolled that in so that if a test did not previously have screening claims the amendment will give that test the serial screening claims and the post-authorization condition requires that validation with asymptomatic individuals. So we wanted to clarify that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Condition F in pooling and serial testing, Post-authorization studies, Validation with asymptomatic individuals
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: What are the validation submission requirements for the pooling aspect of tests under the new amendment?
CLARIFIED ANSWER: The FDA expects the pooling aspect to be validated prior to submission, according to the amendment's guidelines, and included as part of the request for addition to the exhibit.
VERBATIM QUESTION: What are the validation submission requirements for the pooling aspect of tests under the new amendment?
VERBATIM ANSWER: The pooling aspect we do expect to be validated ahead of time as outlined in the amendment. And those - that validation should be submitted as part of your request to be added to the exhibit.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: validation requirements, pooling, testing amendment
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: What guidance is provided in the serial screening supplemental template for tests claiming screening prior to validation with asymptomatic individuals?
CLARIFIED ANSWER: The FDA's serial screening supplemental template outlines a pathway for authorizing screening claims for tests prior to validation with asymptomatic individuals. The guidance requires a post-authorization condition mandating validation with asymptomatic individuals.
VERBATIM QUESTION: What guidance is provided in the serial screening supplemental template for tests claiming screening prior to validation with asymptomatic individuals?
VERBATIM ANSWER: The post-authorization condition lines up with the approach that we outlined in the serial screening supplemental template that we posted last month. March 16th I believe. That provided a path for authorization of screening claims prior to validation with asymptomatic individuals. So under this amendment we've rolled that in so that if a test did not previously have screening claims the amendment will give that test the serial screening claims and the post-authorization condition requires that validation with asymptomatic individuals.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Serial screening guidance, Validation with asymptomatic individuals, Post-authorization conditions
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: What are the paths to authorization for tests that did not previously have screening claims under the new pooling and serial testing amendment?
CLARIFIED ANSWER: The FDA has provided a path for tests without prior screening claims to gain serial screening claims under the pooling and serial testing amendment. This requires post-authorization validation with asymptomatic individuals.
VERBATIM QUESTION: What are the paths to authorization for tests that did not previously have screening claims under the new pooling and serial testing amendment?
VERBATIM ANSWER: That provided a path for authorization of screening claims prior to validation with asymptomatic individuals. So under this amendment we've rolled that in so that if a test did not previously have screening claims the amendment will give that test the serial screening claims and the post-authorization condition requires that validation with asymptomatic individuals.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pooling and serial testing, screening claims, asymptomatic validation
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: Are there specific validation options for tests lacking CT scores in pooling scenarios?
CLARIFIED ANSWER: The FDA provides two validation options for media pooling, with Option 2 applicable for tests that do not rely on CT scores.
VERBATIM QUESTION: Are there specific validation options for tests lacking CT scores in pooling scenarios?
VERBATIM ANSWER: For example, there are, you know, some of the validation approaches require the use of CT scores and some tests don't return CT scores. So there are two validation options for media pooling. Option 2, I believe it is, does not rely on CT scores so that would likely be the applicable validation option for a test that does not use CT scores.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Validation options, Pooling scenarios, CT scores
REVIEW FLAG: False


#### 2. Pooling and Serial Testing Amendment Eligibility Requirements

QA Block 2-1
CLARIFIED QUESTION: Can both analytical and clinical performance testing for the post-authorization study for asymptomatic individuals be provided post-authorization?
CLARIFIED ANSWER: Analytical and clinical performance testing can only be provided post-authorization if the test meets the eligibility requirements of the pooling and serial testing amendment, including meeting specific performance criteria and validation specifications.
VERBATIM QUESTION: Can both analytical and clinical performance testing for the post-authorization study for asymptomatic individuals be provided post-authorization?
VERBATIM ANSWER: The pooling and serial testing amendment is only applicable to previously authorized tests that meet the eligibility requirements as stated in the amendment. So this includes having specific performance criteria per specific validation and design specifications as authorized in the underlying EUA. For example, a previously authorized test that was validated with contrived specimens or for which the PPA is less than 95% would not fall under this amendment. Similarly, a test that does not have multiple targets on SARS-CoV-2 genome or a multi-analyte test would also not fall under this amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: post-authorization testing, performance criteria, pooling amendment
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: Do amendments to an existing EUA include all instruments that are part of the existing authorization if they are eligible?
CLARIFIED ANSWER: Yes, amendments to an existing EUA include all eligible instruments from the existing authorization if they meet the amendment's criteria.
VERBATIM QUESTION: Do amendments to an existing EUA include all instruments that are part of the existing authorization if they are eligible?
VERBATIM ANSWER: For tests that do meet the criteria for the amendment the test configuration as authorized would be amended. So if that includes multiple instruments that would carry through in the amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA amendments, instrument eligibility
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What are the eligibility requirements for a test to qualify under the pooling and serial testing amendment?
CLARIFIED ANSWER: To qualify under the pooling and serial testing amendment, tests must be previously authorized and meet specific performance criteria, including validation and design specifications aligned with the underlying EUA. Tests validated with contrived specimens, with a PPA below 95%, lacking multiple SARS-CoV-2 genome targets, or being non-multi-analyte do not qualify.
VERBATIM QUESTION: What are the eligibility requirements for a test to qualify under the pooling and serial testing amendment?
VERBATIM ANSWER: The pooling and serial testing amendment is only applicable to previously authorized tests that meet the eligibility requirements as stated in the amendment. So this includes having specific performance criteria per specific validation and design specifications as authorized in the underlying EUA. For example, a previously authorized test that was validated with contrived specimens or for which the PPA is less than 95% would not fall under this amendment. Similarly, a test that does not have multiple targets on SARS-CoV-2 genome or a multi-analyte test would also not fall under this amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Eligibility criteria, Pooling and serial testing amendment
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: Why are tests validated with contrived specimens or with a PPA below 95% excluded from the pooling and serial testing amendment?
CLARIFIED ANSWER: The FDA excludes tests validated with contrived specimens or with a PPA below 95% from the pooling and serial testing amendment because they do not meet the eligibility requirements, including specific performance and validation criteria.
VERBATIM QUESTION: Why are tests validated with contrived specimens or with a PPA below 95% excluded from the pooling and serial testing amendment?
VERBATIM ANSWER: The pooling and serial testing amendment is only applicable to previously authorized tests that meet the eligibility requirements as stated in the amendment. So this includes having specific performance criteria per specific validation and design specifications as authorized in the underlying EUA. For example, a previously authorized test that was validated with contrived specimens or for which the PPA is less than 95% would not fall under this amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pooling and serial testing amendment, test validation criteria, PPA requirements
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Are tests without multiple targets on the SARS-CoV-2 genome or not classified as multi-analyte automatically ineligible for the pooling and serial testing amendment?
CLARIFIED ANSWER: Tests without multiple targets on the SARS-CoV-2 genome or not classified as multi-analyte are ineligible for the pooling and serial testing amendment.
VERBATIM QUESTION: Are tests without multiple targets on the SARS-CoV-2 genome or not classified as multi-analyte automatically ineligible for the pooling and serial testing amendment?
VERBATIM ANSWER: Similarly, a test that does not have multiple targets on SARS-CoV-2 genome or a multi-analyte test would also not fall under this amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Eligibility for pooling/serial testing amendment, Multi-analyte tests, SARS-CoV-2 genome targets
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: If a test meets the criteria for the pooling and serial testing amendment, how are multiple instruments included in the test configuration processed under the amendment?
CLARIFIED ANSWER: If a test meets the criteria for the pooling and serial testing amendment, the authorized test configuration will be amended, and this includes multiple instruments if they are part of the original authorization.
VERBATIM QUESTION: If a test meets the criteria for the pooling and serial testing amendment, how are multiple instruments included in the test configuration processed under the amendment?
VERBATIM ANSWER: For tests that do meet the criteria for the amendment the test configuration as authorized would be amended. So if that includes multiple instruments that would carry through in the amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pooling and serial testing amendment, Multiple instruments, Test configuration
REVIEW FLAG: False


#### 3. Validation Requirements and Processes for Amendment Compliance

QA Block 3-1
CLARIFIED QUESTION: What are the specific metrics required for validation under the amendment?
CLARIFIED ANSWER: The amendment requires specific validation metrics outlined in multiple appendices tailored to various indications. These include pooling validation for samples over an N of 3, alongside other information such as pooling procedures and updated labeling, all to be submitted before tests are offered under the amendment.
VERBATIM QUESTION: What are the specific metrics required for validation under the amendment?
VERBATIM ANSWER: The amendment letter includes multiple appendices for different indications and different validation options. So those appendices include the validation requirements to meet the conditions of the amendment. And I know that, you know a lot of times we talk about our validation recommendations or expectations which is, you know, sort of what we refer to as guidance language. The amendment is different. These are requirements. These are specific metrics that must be met in order to qualify under the amendment. So the amendment spells out those requirements and it outlines a process for an EUA holder to submit the required validation for the indication that they're requesting. And the expectation is that that pooling validation as outlined in the applicable appendix is submitted along with the request to be added to the exhibit for the amendment. And that would be for anything pooling over an N of 3 as the amendment does provide for pooling up to and equal 3 without additional pooling validation. And that request for it to be added to the exhibit of the amendment would include, in addition to that validation data, would also include the other information that's outlined in the amendment such as the pooling procedures and the updated labeling. And that all needs to be submitted prior to the test being offered for an indication under the amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Validation metrics, Amendment requirements, Pooling procedures
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What process should an EUA holder follow to submit validation data for a specific indication?
CLARIFIED ANSWER: EUA holders must follow the process outlined in the amendment, which includes submitting validation data as specified in the applicable appendix, along with a request to be added to the amendment exhibit. Submission requires pooling validation (if applicable), pooling procedures, updated labeling, and adherence to conditions spelled out in the amendment. This must occur before offering the test for the specified indication.
VERBATIM QUESTION: What process should an EUA holder follow to submit validation data for a specific indication?
VERBATIM ANSWER: The amendment letter includes multiple appendices for different indications and different validation options. So those appendices include the validation requirements to meet the conditions of the amendment. The amendment spells out those requirements and it outlines a process for an EUA holder to submit the required validation for the indication that they're requesting. And the expectation is that that pooling validation as outlined in the applicable appendix is submitted along with the request to be added to the exhibit for the amendment. And that would be for anything pooling over an N of 3 as the amendment does provide for pooling up to and equal 3 without additional pooling validation. And that request for it to be added to the exhibit of the amendment would include, in addition to that validation data, would also include the other information that's outlined in the amendment such as the pooling procedures and the updated labeling. And that all needs to be submitted prior to the test being offered for an indication under the amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission process, Validation requirements, Amendment conditions
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Are there any validation exemptions for pooling procedures when pools are up to and equal to an N of 3?
CLARIFIED ANSWER: Pooling procedures for up to and equal to an N of 3 are exempt from additional validation under the amendment.
VERBATIM QUESTION: Are there any validation exemptions for pooling procedures when pools are up to and equal to an N of 3?
VERBATIM ANSWER: The amendment does provide for pooling up to and equal 3 without additional pooling validation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pooling procedures, validation exemptions, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What details must be included in the validation submission to add a test to the exhibit of the amendment?
CLARIFIED ANSWER: To add a test to the exhibit of the amendment, the submission must include required validation data, pooling procedures, updated labeling, and any other information outlined in the amendment. This must be submitted prior to offering the test under the amendment.
VERBATIM QUESTION: What details must be included in the validation submission to add a test to the exhibit of the amendment?
VERBATIM ANSWER: The amendment spells out those requirements and it outlines a process for an EUA holder to submit the required validation for the indication that they're requesting. And the expectation is that that pooling validation as outlined in the applicable appendix is submitted along with the request to be added to the exhibit for the amendment. And that would be for anything pooling over an N of 3 as the amendment does provide for pooling up to and equal 3 without additional pooling validation. And that request for it to be added to the exhibit of the amendment would include, in addition to that validation data, would also include the other information that's outlined in the amendment such as the pooling procedures and the updated labeling. And that all needs to be submitted prior to the test being offered for an indication under the amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: validation submission, amendment requirements, pooling procedures
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What updated labeling requirements are necessary for submission under the amendment?
CLARIFIED ANSWER: The submission request under the amendment must include validation data, pooling procedures, and updated labeling, all of which must be submitted before the test is offered for an indication under the amendment.
VERBATIM QUESTION: What updated labeling requirements are necessary for submission under the amendment?
VERBATIM ANSWER: That request for it to be added to the exhibit of the amendment would include, in addition to that validation data, would also include the other information that's outlined in the amendment such as the pooling procedures and the updated labeling. And that all needs to be submitted prior to the test being offered for an indication under the amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: updated labeling requirements, submission under amendment, validation data
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: What are the expectations for pooling procedures to comply with the amendment?
CLARIFIED ANSWER: FDA requires pooling validation for pools over N=3 to be submitted alongside the request for inclusion in the amendment exhibit. This must also include validation data, pooling procedures, updated labeling, and other required information before offering the test for the amendment's indication.
VERBATIM QUESTION: What are the expectations for pooling procedures to comply with the amendment?
VERBATIM ANSWER: The expectation is that that pooling validation as outlined in the applicable appendix is submitted along with the request to be added to the exhibit for the amendment. And that would be for anything pooling over an N of 3 as the amendment does provide for pooling up to and equal 3 without additional pooling validation. And that request for it to be added to the exhibit of the amendment would include, in addition to that validation data, would also include the other information that's outlined in the amendment such as the pooling procedures and the updated labeling. And that all needs to be submitted prior to the test being offered for an indication under the amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pooling validation requirements, EUA amendment compliance
REVIEW FLAG: False


#### 4. Guidelines for Pooled Testing and Validation Requirements

QA Block 4-1
CLARIFIED QUESTION: Is pooling without preauthorization from FDA limited to pools of three?
CLARIFIED ANSWER: Pooling is not entirely without preauthorization; testing up to three specimens can occur without additional validation if amendment requirements are met, but a request must still be submitted to FDA first.
VERBATIM QUESTION: Is pooling without preauthorization from FDA limited to pools of three?
VERBATIM ANSWER: The pooling and serial testing amendment is not quite pooling without preauthorization. For pooling up to three we don't ask for any additional validations when the other requirements of the amendment are met. But the request under the amendment does need to be submitted to FDA prior to a test being offered for that indication.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pooling requirements, FDA preauthorization, serial testing amendment
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Does the pooling and serial testing amendment apply to different specimen types including saliva or is it limited to anterior nasal swab specimens?
CLARIFIED ANSWER: The pooling and serial testing amendment applies only to anterior nasal swab specimens and is for pooled testing of asymptomatic individuals tested weekly as part of a Serial Testing Program.
VERBATIM QUESTION: Does the pooling and serial testing amendment apply to different specimen types including saliva or is it limited to anterior nasal swab specimens?
VERBATIM ANSWER: The amendment is limited to anterior nasal swab specimens. And the indications are for pooled testing of asymptomatic individuals tested at least weekly as part of a Serial Testing Program.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pooling amendment limitations, Specimen types, Serial Testing Program
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Does testing pooled specimens outside of Serial Testing Programs fall under the pooling and serial testing amendment?
CLARIFIED ANSWER: Testing pooled specimens outside of Serial Testing Programs does not fall under the pooling and serial testing amendment, as its validation requirements are specific to pooled serial screening.
VERBATIM QUESTION: Does testing pooled specimens outside of Serial Testing Programs fall under the pooling and serial testing amendment?
VERBATIM ANSWER: This question is asking also about testing pooled specimens outside of Serial Testing Programs. So that would not fall under this amendment. The validation requirements are for that pooled serial screening.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pooled testing, serial testing requirements, validation of test methods
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: How can a sponsor offer pooled testing outside of a Serial Testing Program or use specimen types other than anterior nasal swabs?
CLARIFIED ANSWER: Sponsors can submit a supplemental EUA request to offer pooled testing outside of a Serial Testing Program or with specimen types other than anterior nasal swabs. Anterior nasal swabs may follow validation approaches in the amendment. Saliva pooling is not authorized, and FDA recommends following the EUA template validation.
VERBATIM QUESTION: How can a sponsor offer pooled testing outside of a Serial Testing Program or use specimen types other than anterior nasal swabs?
VERBATIM ANSWER: If a sponsor is interested in offering pooled testing separate from a Serial Testing Program or offering pooled testing with specimen types other than anterior nasal swabs you can submit a supplemental EUA request to your underlying EUA to request those claims. For pooling of anterior nasal swabs separate from a Serial Testing Program you can consider the same validation approaches that are in the appendices of the amendment. However, since we have not yet authorized saliva pooling and we have in some cases seen data for saliva pooling that does not look promising, we do continue to recommend the validation as outlined in the EUA template. And if you have alternate approaches that you'd like to discuss you can reach out with questions or submit a pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pooled testing, specimen types, EUA submission
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What validation approaches can be considered for pooling anterior nasal swabs separate from a Serial Testing Program?
CLARIFIED ANSWER: The FDA recommends using the same validation approaches outlined in the appendices of the amendment for pooling anterior nasal swabs separate from a Serial Testing Program. Saliva pooling is not yet authorized, and the FDA advises to follow the EUA template or consult them for alternative approaches.
VERBATIM QUESTION: What validation approaches can be considered for pooling anterior nasal swabs separate from a Serial Testing Program?
VERBATIM ANSWER: For pooling of anterior nasal swabs separate from a Serial Testing Program you can consider the same validation approaches that are in the appendices of the amendment. However, since we have not yet authorized saliva pooling and we have in some cases seen data for saliva pooling that does not look promising, we do continue to recommend the validation as outlined in the EUA template. And if you have alternate approaches that you'd like to discuss you can reach out with questions or submit a pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pooling anterior nasal swabs, Validation approaches, EUA guidelines
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: Has the FDA authorized saliva pooling for testing under these amendments?
CLARIFIED ANSWER: The FDA has not authorized saliva pooling for testing due to unpromising data and recommends following EUA template validation guidance.
VERBATIM QUESTION: Has the FDA authorized saliva pooling for testing under these amendments?
VERBATIM ANSWER: However, since we have not yet authorized saliva pooling and we have in some cases seen data for saliva pooling that does not look promising, we do continue to recommend the validation as outlined in the EUA template.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Saliva pooling, Testing validation, EUA amendments
REVIEW FLAG: False

QA Block 4-8
CLARIFIED QUESTION: What should sponsors do if they have alternate approaches for validation they wish to discuss?
CLARIFIED ANSWER: Sponsors with alternate validation approaches should contact the FDA with questions or submit a pre-EUA.
VERBATIM QUESTION: What should sponsors do if they have alternate approaches for validation they wish to discuss?
VERBATIM ANSWER: And if you have alternate approaches that you'd like to discuss you can reach out with questions or submit a pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: validation approaches, pre-EUA submissions
REVIEW FLAG: False

QA Block 4-9
CLARIFIED QUESTION: What is the process for submitting a request under the pooling and serial testing amendment?
CLARIFIED ANSWER: Requests under the pooling and serial testing amendment must be submitted to the FDA before offering the test for use.
VERBATIM QUESTION: What is the process for submitting a request under the pooling and serial testing amendment?
VERBATIM ANSWER: The request under the amendment does need to be submitted to FDA prior to a test being offered for that indication.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pooling and serial testing amendment, submission process
REVIEW FLAG: False

QA Block 4-10
CLARIFIED QUESTION: What specific information needs to be included in a supplemental EUA request for pooled testing outside of a Serial Testing Program?
CLARIFIED ANSWER: Sponsors can use validation approaches in the amendment appendices for anterior nasal swab pooling outside a Serial Testing Program. FDA recommends following EUA template validation requirements, especially since saliva pooling is not yet authorized.
VERBATIM QUESTION: What specific information needs to be included in a supplemental EUA request for pooled testing outside of a Serial Testing Program?
VERBATIM ANSWER: If a sponsor is interested in offering pooled testing separate from a Serial Testing Program or offering pooled testing with specimen types other than anterior nasal swabs you can submit a supplemental EUA request to your underlying EUA to request those claims. For pooling of anterior nasal swabs separate from a Serial Testing Program you can consider the same validation approaches that are in the appendices of the amendment. However, since we have not yet authorized saliva pooling and we have in some cases seen data for saliva pooling that does not look promising, we do continue to recommend the validation as outlined in the EUA template. And if you have alternate approaches that you'd like to discuss you can reach out with questions or submit a pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Supplemental EUA request, Pooled testing, Validation requirements
REVIEW FLAG: False

QA Block 4-11
CLARIFIED QUESTION: What are the FDA's expectations for data validation when pooling saliva specimens, despite saliva pooling not being authorized?
CLARIFIED ANSWER: The FDA has not authorized saliva pooling and has observed some unpromising data. They recommend following the validation outlined in the EUA template or contacting them to discuss alternate approaches or submitting a pre-EUA.
VERBATIM QUESTION: What are the FDA's expectations for data validation when pooling saliva specimens, despite saliva pooling not being authorized?
VERBATIM ANSWER: However, since we have not yet authorized saliva pooling and we have in some cases seen data for saliva pooling that does not look promising, we do continue to recommend the validation as outlined in the EUA template. And if you have alternate approaches that you'd like to discuss you can reach out with questions or submit a pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Saliva specimen pooling, Data validation requirements, FDA EUA recommendations
REVIEW FLAG: False

QA Block 4-12
CLARIFIED QUESTION: Are there specific reasons the FDA has observed poor performance data for saliva pooling, and should alternate specimen types be considered instead?
CLARIFIED ANSWER: The FDA has not authorized saliva pooling due to some unpromising data observed. Validation following the EUA template is recommended, and alternate approaches can be discussed directly with the FDA or through a pre-EUA submission.
VERBATIM QUESTION: Are there specific reasons the FDA has observed poor performance data for saliva pooling, and should alternate specimen types be considered instead?
VERBATIM ANSWER: However, since we have not yet authorized saliva pooling and we have in some cases seen data for saliva pooling that does not look promising, we do continue to recommend the validation as outlined in the EUA template. And if you have alternate approaches that you'd like to discuss you can reach out with questions or submit a pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: saliva pooling, validation recommendations, alternate specimen types
REVIEW FLAG: False

QA Block 4-13
CLARIFIED QUESTION: What should be included in a pre-EUA submission when proposing alternate approaches for validation?
CLARIFIED ANSWER: FDA advises contacting them with questions or submitting a pre-EUA when proposing alternate validation approaches.
VERBATIM QUESTION: What should be included in a pre-EUA submission when proposing alternate approaches for validation?
VERBATIM ANSWER: If you have alternate approaches that you'd like to discuss you can reach out with questions or submit a pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pre-EUA submissions, validation proposals, alternate approaches
REVIEW FLAG: False

QA Block 4-14
CLARIFIED QUESTION: What are the detailed validation requirements for anterior nasal swabs as outlined in the appendices of the amendment?
CLARIFIED ANSWER: The validation requirements for anterior nasal swabs for pooled serial screening are outlined in the appendices of the amendment and should be submitted prior to testing. These approaches can also apply to anterior nasal swabs used separately from a Serial Testing Program.
VERBATIM QUESTION: What are the detailed validation requirements for anterior nasal swabs as outlined in the appendices of the amendment?
VERBATIM ANSWER: The validation requirements are for that pooled serial screening. The anterior nasal swab is - are laid out in the appendices of the amendment and should be submitted ahead of testing. If a sponsor is interested in offering pooled testing separate from a Serial Testing Program or offering pooled testing with specimen types other than anterior nasal swabs you can submit a supplemental EUA request to your underlying EUA to request those claims. For pooling of anterior nasal swabs separate from a Serial Testing Program you can consider the same validation approaches that are in the appendices of the amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: validation requirements, anterior nasal swabs, amendment appendices
REVIEW FLAG: False


#### 5. CLIA Requirements and Physician Authorization Clarifications

QA Block 5-1
CLARIFIED QUESTION: Is physician authorization required for the pooling and serial testing amendment?
CLARIFIED ANSWER: Physician authorization remains required; the amendment does not change the prescription status of the EUA.
VERBATIM QUESTION: Is physician authorization required for the pooling and serial testing amendment?
VERBATIM ANSWER: The pooling and serial testing amendment does not change the prescription status of the previously authorized EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pooling and serial testing amendment, physician authorization
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Could CMS do anything about making a CLIA Waiver not required?
CLARIFIED ANSWER: FDA suggests reaching out to CMS for questions about CLIA requirements. A CLIA certificate is required for facility-performed tests, but self-testing with tests authorized for home use does not require a CLIA certificate.
VERBATIM QUESTION: Could CMS do anything about making a CLIA Waiver not required?
VERBATIM ANSWER: You know, we would suggest that you reach out directly to CMS about any questions related to CLIA requirements. Our understanding that we've discussed on this call before is that a CLIA certificate is needed any time a test is performed by a facility and that self-testing using a test authorized for home use would not require a CLIA certificate.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA waiver requirements, Home testing exemptions
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: Does the pooling and serial testing amendment impact the prescription status of EUA tests?
CLARIFIED ANSWER: The pooling and serial testing amendment does not alter the prescription status of previously authorized EUA tests.
VERBATIM QUESTION: Does the pooling and serial testing amendment impact the prescription status of EUA tests?
VERBATIM ANSWER: The pooling and serial testing amendment does not change the prescription status of the previously authorized EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pooling and serial testing, EUA prescription status
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: When is a CLIA certificate required for facilities performing COVID-19 tests?
CLARIFIED ANSWER: A CLIA certificate is required whenever a facility performs a COVID-19 test. However, self-testing with a test authorized for home use does not require a CLIA certificate.
VERBATIM QUESTION: When is a CLIA certificate required for facilities performing COVID-19 tests?
VERBATIM ANSWER: Our understanding that we've discussed on this call before is that a CLIA certificate is needed any time a test is performed by a facility and that self-testing using a test authorized for home use would not require a CLIA certificate.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA certificate requirements, COVID-19 facility testing, Self-testing
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: Does self-testing with home-use authorized tests require a CLIA certificate?
CLARIFIED ANSWER: FDA clarified that self-testing with tests authorized for home use does not require a CLIA certificate, whereas a CLIA certificate is needed when testing is performed at a facility.
VERBATIM QUESTION: Does self-testing with home-use authorized tests require a CLIA certificate?
VERBATIM ANSWER: Our understanding that we've discussed on this call before is that a CLIA certificate is needed any time a test is performed by a facility and that self-testing using a test authorized for home use would not require a CLIA certificate.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA certificate, home-use tests, self-testing
REVIEW FLAG: False


#### 6. Monitoring COVID-19 Tests Against Viral Mutations

QA Block 6-1
CLARIFIED QUESTION: What is the process for monitoring the impact of viral mutations on COVID-19 tests?
CLARIFIED ANSWER: FDA is monitoring the impact of viral mutations on COVID-19 tests and provides updates on the SARS-CoV-2 viral mutations webpage.
VERBATIM QUESTION: What is the process for monitoring the impact of viral mutations on COVID-19 tests?
VERBATIM ANSWER: There is a question about the sensitivity of rapid tests for variants. And at this time we don't have any reason for concern regarding the sensitivity of currently authorized rapid COVID-19 tests. And we are still monitoring the impact of viral mutations on COVID-19 tests. And we do have the new SARS-CoV-2 viral mutations web page that we put out last month, I think, that we will update when additional information becomes available.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: viral mutations, COVID-19 test sensitivity, monitoring updates
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: How frequently is the SARS-CoV-2 viral mutations web page updated?
CLARIFIED ANSWER: The SARS-CoV-2 viral mutations web page is updated when additional information becomes available.
VERBATIM QUESTION: How frequently is the SARS-CoV-2 viral mutations web page updated?
VERBATIM ANSWER: We do have the new SARS-CoV-2 viral mutations web page that we put out last month, I think, that we will update when additional information becomes available.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 mutations, Web page updates
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: What criteria would trigger updates or changes to rapid test sensitivity assessments?
CLARIFIED ANSWER: The FDA is monitoring the impact of viral mutations on COVID-19 tests and will update its SARS-CoV-2 viral mutations webpage as new information becomes available.
VERBATIM QUESTION: What criteria would trigger updates or changes to rapid test sensitivity assessments?
VERBATIM ANSWER: We are still monitoring the impact of viral mutations on COVID-19 tests. And we do have the new SARS-CoV-2 viral mutations web page that we put out last month, I think, that we will update when additional information becomes available.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: rapid test sensitivity, viral mutations monitoring, FDA updates
REVIEW FLAG: False


#### 7. Validating Molecular Tests Using Banked Samples: Key Considerations

QA Block 7-1
CLARIFIED QUESTION: Can banked samples be used to supplement if 30 symptomatic positive samples are not achieved after 2 weeks of enrollment?
CLARIFIED ANSWER: Banked samples may be used to supplement missing symptomatic positive samples, depending on the intended use. For a screening claim, negative specimens should come from asymptomatic individuals. For a symptomatic or suspected COVID claim, specimens from both symptomatic and asymptomatic individuals are acceptable.
VERBATIM QUESTION: Can banked samples be used to supplement if 30 symptomatic positive samples are not achieved after 2 weeks of enrollment?
VERBATIM ANSWER: This will depend a little bit on the indication that you're looking for. To support a screening claim we do recommend that negative specimens come from the intended use population so asymptomatic individuals. To support a suspected of COVID claim or symptomatic claim we have accepted specimens from both asymptomatic and symptomatic individuals since both populations can be considered suspected of COVID-19.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Banked samples, Validation criteria, COVID-19 testing
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: Should negative banked samples also be tested?
CLARIFIED ANSWER: The FDA states that whether negative banked samples should be tested depends on the test's intended purpose. For screening claims, negative samples should come from asymptomatic individuals. For suspected COVID or symptomatic claims, samples from both asymptomatic and symptomatic individuals are acceptable.
VERBATIM QUESTION: Should negative banked samples also be tested?
VERBATIM ANSWER: They're asking whether some negative banked samples should also be tested and if the banked samples need to come from symptomatic subjects or if they can be from any positive or negative samples. So this will depend a little bit on the indication that you're looking for. To support a screening claim we do recommend that negative specimens come from the intended use population so asymptomatic individuals. To support a suspected of COVID claim or symptomatic claim we have accepted specimens from both asymptomatic and symptomatic individuals since both populations can be considered suspected of COVID-19.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Negative banked samples, Sample population, Screening vs symptomatic claims
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: Do banked samples need to come from symptomatic subjects, or can they come from any positive or negative samples?
CLARIFIED ANSWER: Banked samples can come from either symptomatic or asymptomatic individuals, depending on the intended claim. For screening, negative samples should be from asymptomatic individuals. For suspected COVID or symptomatic claims, both symptomatic and asymptomatic samples are acceptable.
VERBATIM QUESTION: Do banked samples need to come from symptomatic subjects, or can they come from any positive or negative samples?
VERBATIM ANSWER: So this will depend a little bit on the indication that you're looking for. To support a screening claim we do recommend that negative specimens come from the intended use population so asymptomatic individuals. To support a suspected of COVID claim or symptomatic claim we have accepted specimens from both asymptomatic and symptomatic individuals since both populations can be considered suspected of COVID-19.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Banked sample use, Symptomatic vs asymptomatic samples, Screening and diagnostic claims
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: If banked samples are used to supplement, do they need to be the same sample type as what is claimed in the IFU?
CLARIFIED ANSWER: The FDA expects banked samples to be the same type as claimed in the IFU. For instance, if a direct swab is claimed, the clinical validation study should use direct swabs.
VERBATIM QUESTION: If banked samples are used to supplement, do they need to be the same sample type as what is claimed in the IFU?
VERBATIM ANSWER: We would expect that the banked samples should be the same sample type that you intend to claim for your device. So if you are claiming a direct swab for your test then we would want to see direct swabs used in the clinical validation study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: banked samples, clinical validation, sample type requirements
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: If the sample type claimed is direct samples with no transport media but the banked samples are in transport media, is that acceptable?
CLARIFIED ANSWER: The FDA expects banked samples used for clinical validation to be the same sample type as claimed for the device. For example, if the device claims direct swabs, direct swabs should be used in validation.
VERBATIM QUESTION: If the sample type claimed is direct samples with no transport media but the banked samples are in transport media, is that acceptable?
VERBATIM ANSWER: We would expect that the banked samples should be the same sample type that you intend to claim for your device. So if you are claiming a direct swab for your test then we would want to see direct swabs used in the clinical validation study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: sample type consistency, banked sample validation
REVIEW FLAG: False


#### 8. Preparing 510(k) for Molecular SARS-CoV-2 Test

QA Block 8-1
CLARIFIED QUESTION: What does FDA expect to see regarding precision and reproducibility studies for a 510(k) submission for a molecular SARS-CoV-2 test?
CLARIFIED ANSWER: FDA expects precision and reproducibility studies to include at least three sites with multiple operators at each site, and one site can be the manufacturer's if it has an appropriate lab. An EUA authorized high-sensitivity RT-PCR assay may be used as the comparator instead of BioFire, which is the only currently legally marketed predicate.
VERBATIM QUESTION: What does FDA expect to see regarding precision and reproducibility studies for a 510(k) submission for a molecular SARS-CoV-2 test?
VERBATIM ANSWER: So that is correct that BioFire is the only available legally marketed predicate at this time. We do understand that it may not be feasible to use BioFire as the comparator for your clinical study. So you may use an EUA authorized high-sensitivity RT-PCR assay as your comparator. And to support a 510k a reproducibility study is expected. Your reproducibility study should include different sites in order to evaluate reproducibility across sites and different operators in order to evaluate reproducibility across operators. So we would generally expect three or more sites with multiple operators at each site. And if the manufacturer site has an appropriate lab that can be one of those sites. And I think we've mentioned previously on the call that if you're pursuing a 510k we do suggest that you submit a pre-submission to discuss your proposed validation strategies and comparator methods for review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510(k) submission requirements, SARS-CoV-2 test reproducibility, Validation strategies
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Can the manufacturer site be one of the three sites for reproducibility studies in a 510(k) submission for a molecular SARS-CoV-2 test?
CLARIFIED ANSWER: Yes, the manufacturer site can be one of the three required sites for reproducibility studies in a 510(k), provided it includes an appropriate lab.
VERBATIM QUESTION: Can the manufacturer site be one of the three sites for reproducibility studies in a 510(k) submission for a molecular SARS-CoV-2 test?
VERBATIM ANSWER: So that is correct that BioFire is the only available legally marketed predicate at this time. We do understand that it may not be feasible to use BioFire as the comparator for your clinical study. So you may use an EUA authorized high-sensitivity RT-PCR assay as your comparator. And to support a 510k a reproducibility study is expected. Your reproducibility study should include different sites in order to evaluate reproducibility across sites and different operators in order to evaluate reproducibility across operators. So we would generally expect three or more sites with multiple operators at each site. And if the manufacturer site has an appropriate lab that can be one of those sites.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510(k) submission, reproducibility studies, manufacturer site
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: Can an EUA-authorized high-sensitivity RT-PCR assay be used as the comparator instead of BioFire in clinical studies for a 510(k) submission?
CLARIFIED ANSWER: Yes, an EUA-authorized high-sensitivity RT-PCR assay can be used as a comparator in clinical studies for a 510(k) submission if using BioFire is not feasible.
VERBATIM QUESTION: Can an EUA-authorized high-sensitivity RT-PCR assay be used as the comparator instead of BioFire in clinical studies for a 510(k) submission?
VERBATIM ANSWER: So that is correct that BioFire is the only available legally marketed predicate at this time. We do understand that it may not be feasible to use BioFire as the comparator for your clinical study. So you may use an EUA authorized high-sensitivity RT-PCR assay as your comparator.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA-authorized comparator, 510(k) clinical studies, BioFire alternative
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: Does FDA suggest submitting a pre-submission for proposed validation strategies and comparator methods when pursuing a 510(k) for a molecular SARS-CoV-2 test?
CLARIFIED ANSWER: FDA suggests submitting a pre-submission to discuss proposed validation strategies and comparator methods when pursuing a 510(k) for a molecular SARS-CoV-2 test.
VERBATIM QUESTION: Does FDA suggest submitting a pre-submission for proposed validation strategies and comparator methods when pursuing a 510(k) for a molecular SARS-CoV-2 test?
VERBATIM ANSWER: I think we've mentioned previously on the call that if you're pursuing a 510k we do suggest that you submit a pre-submission to discuss your proposed validation strategies and comparator methods for review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pre-submission process, Validation strategies, 510(k) for SARS-CoV-2 test
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: What criteria must be met for a manufacturer site to qualify as one of the study sites in a reproducibility study?
CLARIFIED ANSWER: The FDA expects reproducibility studies to include three or more sites with multiple operators at each site. A manufacturer site can be included if it has an appropriate lab.
VERBATIM QUESTION: What criteria must be met for a manufacturer site to qualify as one of the study sites in a reproducibility study?
VERBATIM ANSWER: Your reproducibility study should include different sites in order to evaluate reproducibility across sites and different operators in order to evaluate reproducibility across operators. So we would generally expect three or more sites with multiple operators at each site. And if the manufacturer site has an appropriate lab that can be one of those sites.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: reproducibility study criteria, manufacturer site eligibility, 510k submission
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: Are there specific guidelines for evaluating reproducibility across different operators at each site?
CLARIFIED ANSWER: FDA recommends that reproducibility studies involve three or more sites, including multiple operators at each site, to evaluate reproducibility across both sites and operators. The manufacturer's site can be included if it has an appropriate lab. FDA suggests pre-submission for discussing validation strategies for a 510k.
VERBATIM QUESTION: Are there specific guidelines for evaluating reproducibility across different operators at each site?
VERBATIM ANSWER: Your reproducibility study should include different sites in order to evaluate reproducibility across sites and different operators in order to evaluate reproducibility across operators. So we would generally expect three or more sites with multiple operators at each site. And if the manufacturer site has an appropriate lab that can be one of those sites. And I think we've mentioned previously on the call that if you're pursuing a 510k we do suggest that you submit a pre-submission to discuss your proposed validation strategies and comparator methods for review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k reproducibility studies, operator evaluation, site inclusion
REVIEW FLAG: False


#### 9. Navigating FDA Guidelines for COVID-19 Test Approvals

QA Block 9-1
CLARIFIED QUESTION: Is it realistic to think that FDA may adopt practices similar to the UK and Germany to increase the availability of antigen tests?
CLARIFIED ANSWER: FDA regularly exchanges information with international colleagues, evaluates practices in other countries, and incorporates insights to improve strategies when appropriate.
VERBATIM QUESTION: Is it realistic to think that FDA may adopt practices similar to the UK and Germany to increase the availability of antigen tests?
VERBATIM ANSWER: The U.S. does - we do speak with our international colleagues on a regular basis. And we're familiar with what they do in other countries. And we exchange information all the time. And so we look at what they do and they look at what we do. And sometimes we depend on one another for important information. And that's an ongoing effort. In fact, I have another call tomorrow morning.
SPEAKER QUESTION: Senko Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: International collaboration, Antigen test availability
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Would FDA be amendable to accepting studies from an institute like Karolinska in Sweden for analytical validation?
CLARIFIED ANSWER: The FDA will consider data from any facility, including international ones like Karolinska, as long as the work is done properly. Developers are encouraged to consult the FDA if their methods differ from recommendations. A BSL-3 lab is not required.
VERBATIM QUESTION: Would FDA be amendable to accepting studies from an institute like Karolinska in Sweden for analytical validation?
VERBATIM ANSWER: First of all, we'll look at all available data that a sponsor, a test developer wants to submit to the FDA. You can contract for any of the work with anyone you want as long as it's done well. And, you know, if it's not according to our recommendations we urge you to check with us first through a pre-EUA submission. You know you actually aren't required to use things that require a BSL - you aren't required to do testing that would require a BSL-3 lab. There are different ways to do that. And, you know, I'd reach out directly to the FDA and with the specific questions you have about that. But there are many different ways to address that.
SPEAKER QUESTION: Senko Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Analytical validation, International study acceptance
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: Does it make sense to use a high-performance RT-PCR test with CT values as a comparator instead of tests like Abbott BinaxNOW or QuickVue?
CLARIFIED ANSWER: FDA aims to establish truth with comparator tests by focusing on high-sensitivity molecular tests, especially within the first 5-7 symptomatic days. Alternative approaches can be considered, but robust molecular tests are preferred.
VERBATIM QUESTION: Does it make sense to use a high-performance RT-PCR test with CT values as a comparator instead of tests like Abbott BinaxNOW or QuickVue?
VERBATIM ANSWER: And then as far as the comparator test, what we're trying to establish with the comparator test is truth. And so we are looking for high-sensitivity molecular tests. For antigen direct tests, you know we're looking at performance within the first five to seven days of symptoms and longer if your tests prolongs well over longer periods of time after initiation of symptoms as some of the antigen tests that we've authorized have demonstrated. So we're looking at truth in those first symptomatic days. And that's important so we'll be adhering to that recommendation. If you have - we're always open to alternatives. But, you know, that's what our scientists say is the best thing to do right now.
SPEAKER QUESTION: Senko Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator testing methods, RT-PCR vs. Antigen Tests, Validation approaches
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What are the alternative testing approaches if a BSL-3 lab is unavailable?
CLARIFIED ANSWER: The FDA does not require using a BSL-3 lab for testing. Alternatives include using inactivated virus, such as through heat or irradiation, or diluted actual clinical samples for analysis, as long as the test is not affected by inactivation.
VERBATIM QUESTION: What are the alternative testing approaches if a BSL-3 lab is unavailable?
VERBATIM ANSWER: First of all, we'll look at all available data that a sponsor, a test developer wants to submit to the FDA. You can contract for any of the work with anyone you want as long as it's done well. And, you know, if it's not according to our recommendations we urge you to check with us first through a pre-EUA submission. You know you actually aren't required to use things that require a BSL - you aren't required to do testing that would require a BSL-3 lab. There are different ways to do that. And, you know, I'd reach out directly to the FDA and with the specific questions you have about that. But there are many different ways to address that. And one of them, you know, is to use inactivated virus. Either heat or radiated virus is a good substitute as long as your test isn't impacted by inactivation, that there's flexibilities around using actual clinical samples and diluting them down for analytical studies. So there is no requirement by the FDA to use - to do testing that requires a BSL-3 level lab. So just reach out to us through our template email address or through a pre-EUA to address any of those.
SPEAKER QUESTION: Senko Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: BSL-3 lab alternatives, FDA testing requirements
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: Are inactivated viruses (e.g., heat or radiated) acceptable for analytical studies, and how should they be used?
CLARIFIED ANSWER: Inactivated viruses, such as heat or radiated, are acceptable substitutes for analytical studies as long as the test is not impacted by inactivation. The FDA allows flexibility, including using clinical samples diluted for studies, and recommends contacting them for specific questions.
VERBATIM QUESTION: Are inactivated viruses (e.g., heat or radiated) acceptable for analytical studies, and how should they be used?
VERBATIM ANSWER: First of all, we'll look at all available data that a sponsor, a test developer wants to submit to the FDA. You can contract for any of the work with anyone you want as long as it's done well. And, you know, if it's not according to our recommendations we urge you to check with us first through a pre-EUA submission. You know you actually aren't required to use things that require a BSL - you aren't required to do testing that would require a BSL-3 lab. There are different ways to do that. And, you know, I'd reach out directly to the FDA and with the specific questions you have about that. But there are many different ways to address that. And one of them, you know, is to use inactivated virus. Either heat or radiated virus is a good substitute as long as your test isn't impacted by inactivation, that there's flexibilities around using actual clinical samples and diluting them down for analytical studies.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: inactivated virus, analytical studies, FDA flexibility
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: Can diluted clinical samples be utilized for FDA-required analytical studies, and are there specific guidelines for such use?
CLARIFIED ANSWER: Diluted clinical samples may be used for analytical studies if done appropriately, and FDA provides flexibility in this matter.
VERBATIM QUESTION: Can diluted clinical samples be utilized for FDA-required analytical studies, and are there specific guidelines for such use?
VERBATIM ANSWER: There are flexibilities around using actual clinical samples and diluting them down for analytical studies.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: analytical studies, clinical sample dilution, FDA guidelines
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: Does the FDA routinely consult with international organizations or use data from countries like the UK and Germany in their decision-making process?
CLARIFIED ANSWER: The FDA regularly consults with international colleagues, exchanges information, and sometimes uses their insights for decision-making.
VERBATIM QUESTION: Does the FDA routinely consult with international organizations or use data from countries like the UK and Germany in their decision-making process?
VERBATIM ANSWER: The U.S. does - we do speak with our international colleagues on a regular basis. And we're familiar with what they do in other countries. And we exchange information all the time. And so we look at what they do and they look at what we do. And sometimes we depend on one another for important information. And that's an ongoing effort. In fact, I have another call tomorrow morning.
SPEAKER QUESTION: Senko Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA collaboration with international organizations, Use of international data
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: What criteria does the FDA require to establish 'truth' in comparator tests for antigen tests?
CLARIFIED ANSWER: The FDA uses high-sensitivity molecular tests to establish 'truth' for comparator tests. For antigen tests, performance must be assessed within the first 5-7 days of symptoms and possibly longer if justified.
VERBATIM QUESTION: What criteria does the FDA require to establish 'truth' in comparator tests for antigen tests?
VERBATIM ANSWER: And then as far as the comparator test, what we're trying to establish with the comparator test is truth. And so we are looking for high-sensitivity molecular tests. For antigen direct tests, you know we're looking at performance within the first five to seven days of symptoms and longer if your tests prolongs well over longer periods of time after initiation of symptoms as some of the antigen tests that we've authorized have demonstrated. So we're looking at truth in those first symptomatic days. And that's important so we'll be adhering to that recommendation. If you have - we're always open to alternatives. But, you know, that's what our scientists say is the best thing to do right now.
SPEAKER QUESTION: Senko Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator tests, Truth criteria, Antigen test performance
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: Are there flexibility options for modifying study designs if tests perform well in extended symptomatic periods?
CLARIFIED ANSWER: The FDA evaluates antigen test performance primarily within the first five to seven symptomatic days but may consider longer if tests show effectiveness over extended periods. Alternatives are also open for consideration, but FDA deems this approach currently best.
VERBATIM QUESTION: Are there flexibility options for modifying study designs if tests perform well in extended symptomatic periods?
VERBATIM ANSWER: For antigen direct tests, you know we're looking at performance within the first five to seven days of symptoms and longer if your tests prolongs well over longer periods of time after initiation of symptoms as some of the antigen tests that we've authorized have demonstrated. So we're looking at truth in those first symptomatic days. And that's important so we'll be adhering to that recommendation. If you have - we're always open to alternatives. But, you know, that's what our scientists say is the best thing to do right now.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test performance, Study design flexibility
REVIEW FLAG: False

QA Block 9-10
CLARIFIED QUESTION: Does the FDA have any influence or involvement in the pricing of commercial COVID-19 tests?
CLARIFIED ANSWER: The FDA does not influence or regulate the pricing of commercial COVID-19 tests.
VERBATIM QUESTION: Does the FDA have any influence or involvement in the pricing of commercial COVID-19 tests?
VERBATIM ANSWER: We don't tell commercial test developer what they can or can't charge for a test. The FDA is not involved with that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA role in test pricing, Commercial COVID-19 tests
REVIEW FLAG: False


#### 10. Serology and Antigen Testing Accuracy and Usage Guidelines

QA Block 10-1
CLARIFIED QUESTION: Can you please repeat and explain what you mentioned about the serology testing from 5% to 50%?
CLARIFIED ANSWER: The FDA updated its webpage on EUA-authorized serology test performance to provide information on expected predictive values of serology tests based on prevalence assumptions ranging from 5% to 50%.
VERBATIM QUESTION: Can you please repeat and explain what you mentioned about the serology testing from 5% to 50%?
VERBATIM ANSWER: Sure. Yes, sorry. I was having trouble getting off mute there. So the - we have a web page on the EUA authorized serology test performance. And that web page was updated this morning to provide additional information on the expected predictive value of authorized serology tests when there are prevalence assumptions ranging from 5% to 50%.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Serology testing, Predictive value, Prevalence assumptions
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: What additional data is available on the EUA authorized serology test performance regarding prevalence assumptions between 5% and 50%?
CLARIFIED ANSWER: The FDA updated its web page to include additional information on the predictive value of authorized serology tests, considering prevalence assumptions ranging from 5% to 50%.
VERBATIM QUESTION: What additional data is available on the EUA authorized serology test performance regarding prevalence assumptions between 5% and 50%?
VERBATIM ANSWER: We have a web page on the EUA authorized serology test performance. And that web page was updated this morning to provide additional information on the expected predictive value of authorized serology tests when there are prevalence assumptions ranging from 5% to 50%.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serology test performance, predictive value, COVID-19 testing
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Why is it important to validate antigen test sensitivity with low positive specimens in addition to high positive specimens?
CLARIFIED ANSWER: Antigen test sensitivity is validated with 10%-20% low positive specimens, not only high positive samples, ensuring a broader assessment of test performance.
VERBATIM QUESTION: Why is it important to validate antigen test sensitivity with low positive specimens in addition to high positive specimens?
VERBATIM ANSWER: So first we want to clarify that all antigen tests are validated with data sets that include 10% to 20% of low positive specimens. So the - so it's not quite accurate to say that the sensitivity is established with - only with high positive PCR specimens. They do include low positives.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Antigen test validation, Sensitivity testing
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: What does the FDA consider an appropriate use of antigen test results, given that they are presumptive negatives?
CLARIFIED ANSWER: The FDA states that antigen test results, considered presumptive negatives, should not be used for decisions on isolation or social distancing. Confirmation with a molecular assay is necessary for clinical management.
VERBATIM QUESTION: What does the FDA consider an appropriate use of antigen test results, given that they are presumptive negatives?
VERBATIM ANSWER: The labeling for the antigen test does indicate that these are presumptive negatives and should not be used to make determinations about isolation or social distancing practices. And further that if it's necessary for clinical management the tests results should be confirmed with a molecular assay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: antigen test use, presumptive negative results, molecular assay confirmation
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: Why should antigen test results below 95% sensitivity not be used for isolation or social distancing decisions?
CLARIFIED ANSWER: Antigen tests are labeled as providing presumptive negative results and should not be used to determine isolation or social distancing practices. Confirmatory testing with a molecular assay is recommended for clinical management.
VERBATIM QUESTION: Why should antigen test results below 95% sensitivity not be used for isolation or social distancing decisions?
VERBATIM ANSWER: The labeling for the antigen test does indicate that these are presumptive negatives and should not be used to make determinations about isolation or social distancing practices. And further that if it's necessary for clinical management the tests results should be confirmed with a molecular assay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Antigen test sensitivity, Isolation decisions, Confirmatory molecular testing
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: What is the FDA's stance on the necessity of serial testing for asymptomatic individual identification across all test types?
CLARIFIED ANSWER: The FDA strongly supports serial testing across all test types to enhance the detection of asymptomatic individuals, including rapid point-of-care and home lateral flow tests, despite lower sensitivity levels.
VERBATIM QUESTION: What is the FDA's stance on the necessity of serial testing for asymptomatic individual identification across all test types?
VERBATIM ANSWER: And Toby's absolutely correct in talking about negatives in these tests that are below 95% PPA or sensitivity, are presumed negative. That's standard labeling language that we authorize. And in addition, we really strongly support serial testing of not just these rapid point of care and home lateral flow tests but really of all tests if we want to do our best as a laboratory and healthcare community at capturing and identifying asymptomatic individuals.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serial testing, asymptomatic detection, test sensitivity
REVIEW FLAG: False

QA Block 10-7
CLARIFIED QUESTION: What are the labeling language requirements for rapid point-of-care and home lateral flow antigen tests that have lower sensitivity than central lab molecular tests?
CLARIFIED ANSWER: FDA requires that rapid point-of-care and home lateral flow antigen tests with sensitivity below 95% are labeled as producing presumed negatives, and serial testing is strongly supported for identifying asymptomatic cases.
VERBATIM QUESTION: What are the labeling language requirements for rapid point-of-care and home lateral flow antigen tests that have lower sensitivity than central lab molecular tests?
VERBATIM ANSWER: Toby's absolutely correct in talking about negatives in these tests that are below 95% PPA or sensitivity, are presumed negative. That's standard labeling language that we authorize. And in addition, we really strongly support serial testing of not just these rapid point of care and home lateral flow tests but really of all tests if we want to do our best as a laboratory and healthcare community at capturing and identifying asymptomatic individuals.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: labeling requirements, antigen test sensitivity, serial testing
REVIEW FLAG: False

QA Block 10-8
CLARIFIED QUESTION: What constitutes appropriate clinical management in cases where antigen test results need molecular assay confirmation?
CLARIFIED ANSWER: Antigen test results are presumptive negatives and should not guide isolation or social distancing decisions. If necessary for clinical management, confirm results with a molecular assay.
VERBATIM QUESTION: What constitutes appropriate clinical management in cases where antigen test results need molecular assay confirmation?
VERBATIM ANSWER: The labeling for the antigen test does indicate that these are presumptive negatives and should not be used to make determinations about isolation or social distancing practices. And further that if it's necessary for clinical management the tests results should be confirmed with a molecular assay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Antigen test limitations, Molecular assay confirmation
REVIEW FLAG: False


#### 11. FDA Guidance on Language Usability Testing Requirements

QA Block 11-1
CLARIFIED QUESTION: Would the FDA expect to see usability testing with Chinese-speaking users if a manufacturer intends to provide instructions in English and Chinese in one combined digital IFU?
CLARIFIED ANSWER: The FDA could not confirm and recommended submitting this question for a written response.
VERBATIM QUESTION: Would the FDA expect to see usability testing with Chinese-speaking users if a manufacturer intends to provide instructions in English and Chinese in one combined digital IFU?
VERBATIM ANSWER: I'm not sure. If you can send that question in, we can try and get you a response.
SPEAKER QUESTION: Savannah Estes
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: usability testing, instructions for use, language requirements
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Does the assumption that separate documents may not require Spanish-speaking users in usability testing change the thought process if the instructions are combined or separated?
CLARIFIED ANSWER: The FDA adheres to the recommendations in the template and suggests submitting the question for further clarification.
VERBATIM QUESTION: Does the assumption that separate documents may not require Spanish-speaking users in usability testing change the thought process if the instructions are combined or separated?
VERBATIM ANSWER: Yes. I mean we go by what's in the template as far as our recommendations are concerned. I think that's a great question to send in as Toby recommended.
SPEAKER QUESTION: Savannah Estes
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Usability testing, IFU language requirements, FDA template recommendations
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: How can one enrich a population to accumulate asymptomatic positives for breath test development?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA with the study design to discuss approaches for accumulating asymptomatic positives. Current guidance on required numbers of positives and negatives in validation studies is available via their template email address.
VERBATIM QUESTION: How can one enrich a population to accumulate asymptomatic positives for breath test development?
VERBATIM ANSWER: We're open to enrichment at the - I would ask that you submit a pre-EUA with the study design. And then we can discuss that with you. Our current thinking also provides sort of the number of positives and the number of negatives that we'd like to see in the validation study for these devices. And if you send an email to the template email address we'll respond with those as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Breath test development, Population enrichment, Validation study requirements
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: What are the FDA's current recommendations for usability testing of digital instructions for use in languages other than English and Spanish?
CLARIFIED ANSWER: FDA's current recommendations for over-the-counter tests are focused on instructions in English and Spanish. Developers may add other languages, but further guidance on usability testing for non-English languages is not explicitly addressed and should be submitted as a follow-up question.
VERBATIM QUESTION: What are the FDA's current recommendations for usability testing of digital instructions for use in languages other than English and Spanish?
VERBATIM ANSWER: Toby may know the answer here. I know that our recommendations are English and Spanish in the U.S. for OTC. And certainly developers can add additional language. Toby, do you have - I forget about usability in non-English languages. Do you remember?
SPEAKER QUESTION: Savannah Estes
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Usability testing, Digital IFU languages, FDA recommendations
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: Would the FDA consider updating their template to provide more flexibility for combined or multi-language instructions?
CLARIFIED ANSWER: The FDA will consider updating the template to make it more flexible, as they aim to continuously improve their recommendations.
VERBATIM QUESTION: Would the FDA consider updating their template to provide more flexibility for combined or multi-language instructions?
VERBATIM ANSWER: And we'll take a look at, you know, whether we update the template and make it more flexible, which is always our goal is to constantly review what we do and see how we can improve our recommendations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Template updates, Multi-language instructions, Flexibility in guidance
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: What are the specific requirements for listing a new Class 1 exempt extraction kit under the JJH Pro Code?
CLARIFIED ANSWER: FDA recommends developing Class 1 exempt extraction kits under a 21 CFR Part 820 compliant quality system, registering and listing them under the JJH Pro Code, and collaborating with authorized assay developers for validation and supplemental EUA requests.
VERBATIM QUESTION: What are the specific requirements for listing a new Class 1 exempt extraction kit under the JJH Pro Code?
VERBATIM ANSWER: So generally we would recommend that you work with a test developer. The - generally assays that we authorize under EUA specify the extraction reagents with which the test has been validated and with which the test has been authorized. So if you're developing a new extraction kit those are generally Class 1 exempt devices and can be marketed under the Pro Code JJH. And so you - we would recommend that you develop your device under a 21 CFR Part 820 compliant quality system. And then you can register and list your device under the JJH Pro Code and collaborate with test developers of authorized assays that may be interested in validating their test with your extraction kit. And then those assay developers could submit a supplemental EUA request to add your extraction kit to their authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Class 1 exempt devices, JJH Pro Code, Collaboration with assay developers
REVIEW FLAG: False

QA Block 11-7
CLARIFIED QUESTION: What steps should a developer take to collaborate with assay developers to validate a new extraction kit?
CLARIFIED ANSWER: FDA recommends working with test developers to validate new extraction kits. Developers should comply with a 21 CFR Part 820 quality system, list the device under JJH Pro Code, and collaborate with authorized assay developers. These assay developers can subsequently submit a supplemental EUA request to include the extraction kit.
VERBATIM QUESTION: What steps should a developer take to collaborate with assay developers to validate a new extraction kit?
VERBATIM ANSWER: Generally we would recommend that you work with a test developer. The - generally assays that we authorize under EUA specify the extraction reagents with which the test has been validated and with which the test has been authorized. So if you're developing a new extraction kit those are generally Class 1 exempt devices and can be marketed under the Pro Code JJH. And so you - we would recommend that you develop your device under a 21 CFR Part 820 compliant quality system. And then you can register and list your device under the JJH Pro Code and collaborate with test developers of authorized assays that may be interested in validating their test with your extraction kit. And then those assay developers could submit a supplemental EUA request to add your extraction kit to their authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Extraction kit validation, Collaboration with assay developers, EUA process
REVIEW FLAG: False

QA Block 11-8
CLARIFIED QUESTION: How can a test developer request the FDA's current thinking or draft guidelines for breath test development?
CLARIFIED ANSWER: FDA recommends sending an email to their template email address to request the current draft and thinking on breath test development. A template is being prepared, but its public availability date is not yet available.
VERBATIM QUESTION: How can a test developer request the FDA's current thinking or draft guidelines for breath test development?
VERBATIM ANSWER: You know we have prepared our current thinking for this type of test development. And anyone who's interested in that I would recommend that you ask for those current thoughts for - through our template's email address and our team will provide our current thinking. We are providing - we are preparing a template for the breath test. And we don't know when that can be publicly available. But we do have current drafted thinking and we can share that with you.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Breath test development, FDA draft guidelines, Request process
REVIEW FLAG: False

QA Block 11-9
CLARIFIED QUESTION: What is the recommended number of positive and negative samples for validation studies in breath test devices?
CLARIFIED ANSWER: The FDA has guidance on the number of positive and negative samples for breath test validation studies, which can be obtained by emailing the template email address for the current recommendations.
VERBATIM QUESTION: What is the recommended number of positive and negative samples for validation studies in breath test devices?
VERBATIM ANSWER: Our current thinking also provides sort of the number of positives and the number of negatives that we'd like to see in the validation study for these devices. And if you send an email to the template email address we'll respond with those as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Breath test validation, Sample size recommendations
REVIEW FLAG: False

QA Block 11-10
CLARIFIED QUESTION: What key considerations should be included in a pre-EUA submission for breath test development?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA with study design details for breath tests. Draft guidance suggests targeting asymptomatic populations due to a favorable benefit/risk ratio. Recommendations also include the number of positives and negatives required in validation studies, shared upon request to the template email.
VERBATIM QUESTION: What key considerations should be included in a pre-EUA submission for breath test development?
VERBATIM ANSWER: You know breathing into some sort of device in order to potentially detect SARS-CoV-2. You know we have prepared our current thinking for this type of test development. And anyone who's interested in that I would recommend that you ask for those current thoughts for - through our template's email address and our team will provide our current thinking. We are providing - we are preparing a template for the breath test. And we don't know when that can be publicly available. But we do have current drafted thinking and we can share that with you. There's a specific question about our recommendations around the fact that we do believe that breath tests should - we recommend targeting the asymptomatic population as we think the benefit/risk ratio works best in that situation. And the question had to do with how can one enrich a population to it to make this easier to accumulate the asymptomatic positives? We're open to enrichment at the - I would ask that you submit a pre-EUA with the study design. And then we can discuss that with you. Our current thinking also provides sort of the number of positives and the number of negatives that we'd like to see in the validation study for these devices. And if you send an email to the template email address we'll respond with those as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Breath test validation, Asymptomatic population targeting, Pre-EUA submission
REVIEW FLAG: False


#### 12. Clinical Utility of Companion Diagnostics for Variant Identification

QA Block 12-1
CLARIFIED QUESTION: Will there be any clinical utility for a companion diagnostic test to identify the KLA variant or specific mutations involved with a positive specimen?
CLARIFIED ANSWER: FDA is in discussions with test developers for sequencing-based and genotyping-based assays to detect variants and their clinical utility. They provide validation guidance for developers and distinguish between public health reporting and clinical reporting of genotypic results. Correlations to therapeutics or vaccines require further studies.
VERBATIM QUESTION: Will there be any clinical utility for a companion diagnostic test to identify the KLA variant or specific mutations involved with a positive specimen?
VERBATIM ANSWER: Yes. So right now we are in discussion with a number of test developers both sequencing-based and genotyping-based to bring forward assays where either one of two situations can occur. The first is that the test developer may want to be able to report the genotype or variant or mutation information to the clinician and/or the patient and from the lab. And we're open to that. And we now have prepared recommendations for the validation of such sequencing or genotyping test. So developers can email our template email address and ask for those current - that current thinking. And then there is another pathway that is open. And that is that for test developers who develop a test that both detect SARS-CoV-2 and also genotype or sequence but they, you know, are not wanting to go forward with having those genotype or sequence data reported to clinicians or patients but there is a public health need to - for public health authorities to see that information. So if reporting is only to a public health authority and not to the clinician or patients where the FDA is not going to regulate that genotype or sequencing component of that SARS-CoV-2 detection test. So we would - the FDA would review SARS-CoV-2 detection. And we would make sure that the labeling is appropriate that the genotyping or variant or sequencing information is not transmitted to patients unless validated and authorized by the FDA. You're talking about an extension beyond that and any correlation with specific therapeutics or vaccine. We have not gotten that far in our thinking. I would - always interested in studies and data that show that that's - really has a clinical impact. And, you know, I'm sure at some point it definitely will. So I mean if you have data, publications that, you know, we haven't seen, you can always make sure and forward that to our template's email address and it'll be distributed. We are trying to keep an eye on everything. But we don't necessarily catch everything. And if you have a specific test in development where you would like to make certain claims, you know, submit a pre-EUA and include the information that you think is important. And we'll give you feedback on that.
SPEAKER QUESTION: Eric Penny
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Clinical utility of diagnostic tests, Variant identification, FDA guidance for test developers
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Should we go through the pre-submission process with the templates since we have a full set of analytical and clinical evaluations for all known variants?
CLARIFIED ANSWER: The FDA advises submitting a pre-EUA for feedback if studies are incomplete, or directly submitting an EUA if all studies and data collection are complete.
VERBATIM QUESTION: Should we go through the pre-submission process with the templates since we have a full set of analytical and clinical evaluations for all known variants?
VERBATIM ANSWER: If you've already done all the data collection and you - or if you haven't completed all your studies, if you haven't completed all your studies then immediately send in. As soon as you can, send in a pre-EUA. If you've completed all the studies and you want us to review it for an EUA authorization just, you know, submit that. But we're very happy to give feedback through a pre-EUA for any studies you haven't initiated yet.
SPEAKER QUESTION: Eric Penny
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-submission process, clinical and analytical evaluations, EUA submissions
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: What is FDA's position on a finger stick point of care serology test that uses a full S1 protein antigen and if all performance and criteria in the serology template are included, would this address FDA's concerns on current variants?
CLARIFIED ANSWER: The FDA prioritizes EUA tests that enhance accessibility, including point-of-care serology tests. Adequate performance can be established via validation studies, but this does not fully address concerns about the impact of current or future variants. The serology template includes recommendations for ongoing monitoring and assessing variant impacts.
VERBATIM QUESTION: What is FDA's position on a finger stick point of care serology test that uses a full S1 protein antigen and if all performance and criteria in the serology template are included, would this address FDA's concerns on current variants?
VERBATIM ANSWER: So first, we do currently prioritize review of EUA tests where authorization would increase testing accessibility which would include serology tests intended for use at point of care settings. And that's regardless of the antigens used in the assays to capture the antibodies against SARS-CoV-2. And regarding the concerns about variants we do believe that adequate performance demonstrated in the validation studies is important to establish the performance of the test but it would not necessarily address the concerns regarding the potential impact of current or future variants on assay performance. The serology template does include recommendations to provide a plan for monitoring new and emerging SARS-CoV-2 viral mutations and variants on an ongoing basis and for assessing the impact of mutations and variants that have been identified as prevalent or clinically significant on the performance of your assay over time. So we would recommend that you take a look at those recommendations in the template as you prepare your EUA request.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA review priorities, Point-of-care serology tests, Variants and performance monitoring
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What are the FDA's current recommendations for validating sequencing or genotyping tests intended to report mutation or variant information?
CLARIFIED ANSWER: The FDA has prepared recommendations for validating sequencing or genotyping tests to report variant or mutation information. Developers can request the guidance by emailing the FDA's template email address.
VERBATIM QUESTION: What are the FDA's current recommendations for validating sequencing or genotyping tests intended to report mutation or variant information?
VERBATIM ANSWER: Yes. So right now we are in discussion with a number of test developers both sequencing-based and genotyping-based to bring forward assays where either one of two situations can occur. The first is that the test developer may want to be able to report the genotype or variant or mutation information to the clinician and/or the patient and from the lab. And we're open to that. And we now have prepared recommendations for the validation of such sequencing or genotyping test. So developers can email our template email address and ask for those current - that current thinking.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of sequencing/genotyping tests, Reporting variant/mutation information
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: Under what circumstances will the FDA not regulate the genotyping or sequencing component of a SARS-CoV-2 detection test?
CLARIFIED ANSWER: The FDA will not regulate the genotyping or sequencing component of a SARS-CoV-2 detection test if the data is reported only to public health authorities and not to clinicians or patients.
VERBATIM QUESTION: Under what circumstances will the FDA not regulate the genotyping or sequencing component of a SARS-CoV-2 detection test?
VERBATIM ANSWER: And then there is another pathway that is open. And that is that for test developers who develop a test that both detect SARS-CoV-2 and also genotype or sequence but they, you know, are not wanting to go forward with having those genotype or sequence data reported to clinicians or patients but there is a public health need to - for public health authorities to see that information. So if reporting is only to a public health authority and not to the clinician or patients where the FDA is not going to regulate that genotype or sequencing component of that SARS-CoV-2 detection test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: genotyping/sequencing regulation, SARS-CoV-2 testing, FDA guidelines
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: What labeling requirements must be met to ensure genotyping or variant information is not transmitted to patients without FDA authorization?
CLARIFIED ANSWER: The FDA ensures that labeling prevents genotyping or variant information from being transmitted to patients unless the test is validated and authorized by the agency.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: And we would make sure that the labeling is appropriate that the genotyping or variant or sequencing information is not transmitted to patients unless validated and authorized by the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Labeling requirements, Genotyping or variant information, FDA authorization
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: Can developers submit data or publications directly to the FDA for review and how should they do this?
CLARIFIED ANSWER: Developers can submit data and publications to the FDA by sending them to the provided template email address. If developers have a specific test in development with claims, they should submit a pre-EUA including relevant information for FDA feedback.
VERBATIM QUESTION: Can developers submit data or publications directly to the FDA for review and how should they do this?
VERBATIM ANSWER: So I mean if you have data, publications that, you know, we haven't seen, you can always make sure and forward that to our template's email address and it'll be distributed. We are trying to keep an eye on everything. But we don't necessarily catch everything. And if you have a specific test in development where you would like to make certain claims, you know, submit a pre-EUA and include the information that you think is important. And we'll give you feedback on that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Submitting data to FDA, Pre-EUA process
REVIEW FLAG: False

QA Block 12-8
CLARIFIED QUESTION: Is it advisable to submit a pre-EUA for feedback on studies not yet initiated?
CLARIFIED ANSWER: FDA advises submitting a pre-EUA for feedback on studies not yet initiated, as well as studies in progress, to provide guidance.
VERBATIM QUESTION: Is it advisable to submit a pre-EUA for feedback on studies not yet initiated?
VERBATIM ANSWER: If you've already done all the data collection and you - or if you haven't completed all your studies, if you haven't completed all your studies then immediately send in. As soon as you can, send in a pre-EUA. If you've completed all the studies and you want us to review it for an EUA authorization just, you know, submit that. But we're very happy to give feedback through a pre-EUA for any studies you haven't initiated yet.
SPEAKER QUESTION: Eric Penny
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA submission, FDA feedback, study initiation
REVIEW FLAG: False

QA Block 12-9
CLARIFIED QUESTION: What steps should a developer follow if they have completed all analytical and clinical evaluations and are ready to submit for EUA authorization?
CLARIFIED ANSWER: If all studies are complete, submit for EUA review. If not, send a pre-EUA immediately for feedback. The FDA is happy to assist with uninitiated studies via pre-EUA.
VERBATIM QUESTION: What steps should a developer follow if they have completed all analytical and clinical evaluations and are ready to submit for EUA authorization?
VERBATIM ANSWER: If you've already done all the data collection and you - or if you haven't completed all your studies, if you haven't completed all your studies then immediately send in. As soon as you can, send in a pre-EUA. If you've completed all the studies and you want us to review it for an EUA authorization just, you know, submit that. But we're very happy to give feedback through a pre-EUA for any studies you haven't initiated yet.
SPEAKER QUESTION: Eric Penny
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, Pre-EUA, FDA feedback
REVIEW FLAG: False

QA Block 12-10
CLARIFIED QUESTION: What is the FDA's position on the inability to compare quantitative values between different antigen tests due to the lack of fully quantitative antigen tests or reference material?
CLARIFIED ANSWER: The FDA does not currently have any EUA-authorized fully quantitative COVID-19 antigen tests. Without such tests or established reference materials, the agency cannot evaluate direct comparisons of quantitative values between different antigen tests.
VERBATIM QUESTION: What is the FDA's position on the inability to compare quantitative values between different antigen tests due to the lack of fully quantitative antigen tests or reference material?
VERBATIM ANSWER: We just have a couple left here. So the next one is about a quantitative test for antigens or SARS-CoV-2 antigen tests and asking about comparison between quantitative values between different antigen tests, so we do want to clarify that we do not currently have any EUA authorized quantitative COVID-19 antigen tests. The authorized devices do establish the assay's limit of detection. And they do use different measurements between different tests that are not comparable. So until we have a fully quantitative antigen test or establish reference material, we're not able to evaluate the direct comparisons of the performance and correlation of the quantitative value between those antigen tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Quantitative antigen tests, Comparison between antigen tests
REVIEW FLAG: False

QA Block 12-11
CLARIFIED QUESTION: What plans for ongoing monitoring of mutations and variants should be included in an EUA request for a serology test?
CLARIFIED ANSWER: The FDA recommends including a plan in the EUA request for ongoing monitoring of new and emerging SARS-CoV-2 mutations and variants, as well as assessing their impact on assay performance over time. Details are available in the serology template.
VERBATIM QUESTION: What plans for ongoing monitoring of mutations and variants should be included in an EUA request for a serology test?
VERBATIM ANSWER: The serology template does include recommendations to provide a plan for monitoring new and emerging SARS-CoV-2 viral mutations and variants on an ongoing basis and for assessing the impact of mutations and variants that have been identified as prevalent or clinically significant on the performance of your assay over time. So we would recommend that you take a look at those recommendations in the template as you prepare your EUA request.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serology tests, variant monitoring, EUA preparation
REVIEW FLAG: False


#### 13. Guidelines for Validating Breath Tests for SARS-CoV-2 Detection

QA Block 13-1
CLARIFIED QUESTION: Would it be acceptable to add to the validation test subjects from out of the U.S. for an asymptomatic claim?
CLARIFIED ANSWER: The FDA is open to studies outside the U.S. for validation tests, but it depends on the intended use setting. For point-of-care or home tests, the FDA prefers validation with U.S. home users in a simulated or real U.S. home environment. Developers should discuss their specific validation plans with the FDA.
VERBATIM QUESTION: Would it be acceptable to add to the validation test subjects from out of the U.S. for an asymptomatic claim?
VERBATIM ANSWER: Yes, the breath test, so we do not know the performance of this new kind of technology. We really don't - for respiratory disease. The FDA doesn't have any experience with this. And so in order for us to authorize a brand new technology like this at least in the beginning until we get and demonstrate that it performs as well as more classical tests, we really do need to see that 100 asymptomatic positives, I think is what our current thinking is. We are open to, as I mentioned earlier in addressing a similar question, we're open to enrichment technology or methods. We want to eliminate bias. So if you want to discuss that I would come in and speak and through our template's email address either as a pre-EUA or a question about whether enrichment can be used for those tests. We are open to studies outside the U.S. as well. It does depend on what setting you want this test to be validated and authorized for. But typically this would be a point of care test and/or it can be even an over-the-counter test or a home test. In those situations such as point of care and in the home, we ideally would like to see U.S. home users used. That can be either in their home or it could be in a simulated home environment that a test developer sets up in any facility they want. So some of these breath tests are not necessarily able to be used at point of care at home due to the equipment requirements, and then it may be limited to more of a moderate or high complexity lab setting. And we may be - it may be easier to show performance in the intended place of use if it's a moderately to high complexity test. So I would come in and ask those specific questions to the FDA. And we'll do our best to ease, you know, the path to demonstrate performance of your breath test.
SPEAKER QUESTION: Gabrielle
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic claim tests, breath test validation, international test subjects
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: Is it correct that with 2% prevalence and the requirement for 100 positive asymptomatic cases, approximately 50,000 test subjects would be needed?
CLARIFIED ANSWER: The FDA cannot confirm the exact math, acknowledges that prevalence varies in the U.S., and emphasizes openness to enrichment processes like serial testing to gather sufficient data.
VERBATIM QUESTION: Is it correct that with 2% prevalence and the requirement for 100 positive asymptomatic cases, approximately 50,000 test subjects would be needed?
VERBATIM ANSWER: Well, I can't do the math right now. And prevalence is variable within the U.S. And that's why absolutely we are open to any sort of enrichment process. And, you know, in the past some of these processes could be connecting up with a Serial Testing Program for schools or workplaces or convalescent centers where the catchment is rather large and you can enrich your population that way. You know one of the challenges with this technology is we're really trying to tell how sensitive and specific it is for a virus and not the actual molecules that technologies are developing - are detecting. You know the analytical detection of those molecules can be proven very easily. But, you know, the implications for clinical diagnosis or screening, you know, haven't been demonstrated.
SPEAKER QUESTION: Gabrielle
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: prevalence uncertainty, enrichment processes, testing challenges
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: What additional validation steps are required for the authorization of a breath-based test for respiratory disease?
CLARIFIED ANSWER: The FDA requires initial breath-based test technologies to show performance equal to classical tests, including data from 100 asymptomatic positive cases. They are open to enrichment methods and studies outside the U.S., depending on test settings. Validation may vary depending on whether the test is for point-of-care, over-the-counter, or home use settings. Developers should directly consult FDA templates for specific guidance.
VERBATIM QUESTION: What additional validation steps are required for the authorization of a breath-based test for respiratory disease?
VERBATIM ANSWER: Yes, the breath test, so we do not know the performance of this new kind of technology. We really don't - for respiratory disease. The FDA doesn't have any experience with this. And so in order for us to authorize a brand new technology like this at least in the beginning until we get and demonstrate that it performs as well as more classical tests, we really do need to see that 100 asymptomatic positives, I think is what our current thinking is. We are open to, as I mentioned earlier in addressing a similar question, we're open to enrichment technology or methods. We want to eliminate bias. So if you want to discuss that I would come in and speak and through our template's email address either as a pre-EUA or a question about whether enrichment can be used for those tests. We are open to studies outside the U.S. as well. It does depend on what setting you want this test to be validated and authorized for. But typically this would be a point of care test and/or it can be even an over-the-counter test or a home test. In those situations such as point of care and in the home, we ideally would like to see U.S. home users used. That can be either in their home or it could be in a simulated home environment that a test developer sets up in any facility they want. So some of these breath tests are not necessarily able to be used at point of care at home due to the equipment requirements, and then it may be limited to more of a moderate or high complexity lab setting. And we may be - it may be easier to show performance in the intended place of use if it's a moderately to high complexity test. So I would come in and ask those specific questions to the FDA. And we'll do our best to ease, you know, the path to demonstrate performance of your breath test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Breath-based test validation, FDA test authorization, Clinical validation requirements
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: Can developers use enrichment processes, such as linking with serial testing programs, to meet sample requirements for asymptomatic positive cases?
CLARIFIED ANSWER: The FDA is open to enrichment processes, such as connecting with Serial Testing Programs, to help developers meet sample requirements for asymptomatic positive cases.
VERBATIM QUESTION: Can developers use enrichment processes, such as linking with serial testing programs, to meet sample requirements for asymptomatic positive cases?
VERBATIM ANSWER: And prevalence is variable within the U.S. And that's why absolutely we are open to any sort of enrichment process. And, you know, in the past some of these processes could be connecting up with a Serial Testing Program for schools or workplaces or convalescent centers where the catchment is rather large and you can enrich your population that way.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: enrichment processes, serial testing programs, asymptomatic case samples
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: How does the intended setting for the test's use (e.g., at-home, point-of-care, or laboratory) affect the study design and validation requirements?
CLARIFIED ANSWER: The validation and study design depend on the intended setting. For at-home or point-of-care tests, the FDA prefers testing with U.S. home users, in their homes or simulated environments. Tests requiring complex equipment may be limited to moderate or high complexity laboratory settings.
VERBATIM QUESTION: How does the intended setting for the test's use (e.g., at-home, point-of-care, or laboratory) affect the study design and validation requirements?
VERBATIM ANSWER: It does depend on what setting you want this test to be validated and authorized for. But typically this would be a point of care test and/or it can be even an over-the-counter test or a home test. In those situations such as point of care and in the home, we ideally would like to see U.S. home users used. That can be either in their home or it could be in a simulated home environment that a test developer sets up in any facility they want. So some of these breath tests are not necessarily able to be used at point of care at home due to the equipment requirements, and then it may be limited to more of a moderate or high complexity lab setting. And we may be - it may be easier to show performance in the intended place of use if it's a moderately to high complexity test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test validation by setting, Point-of-care vs laboratory settings, Equipment requirements
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: Are there specific considerations for demonstrating the performance of breath tests in moderately or highly complex lab settings?
CLARIFIED ANSWER: Breath tests may only be usable in moderate or high complexity laboratory settings due to equipment requirements, and it can be easier to demonstrate performance in such settings. The FDA recommends reaching out with specific questions for further guidance.
VERBATIM QUESTION: Are there specific considerations for demonstrating the performance of breath tests in moderately or highly complex lab settings?
VERBATIM ANSWER: Some of these breath tests are not necessarily able to be used at point of care at home due to the equipment requirements, and then it may be limited to more of a moderate or high complexity lab setting. And we may be - it may be easier to show performance in the intended place of use if it's a moderately to high complexity test. So I would come in and ask those specific questions to the FDA. And we'll do our best to ease, you know, the path to demonstrate performance of your breath test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: breath test performance, moderate/high complexity labs, test validation
REVIEW FLAG: False

QA Block 13-7
CLARIFIED QUESTION: What are the FDA's expectations for eliminating bias when employing enrichment methods in test validation studies?
CLARIFIED ANSWER: The FDA is open to enrichment methods or technologies, emphasizing the need to eliminate bias. Developers are encouraged to consult the FDA via the templates email for further guidance on using enrichment in test validation studies.
VERBATIM QUESTION: What are the FDA's expectations for eliminating bias when employing enrichment methods in test validation studies?
VERBATIM ANSWER: We are open to, as I mentioned earlier in addressing a similar question, we're open to enrichment technology or methods. We want to eliminate bias. So if you want to discuss that I would come in and speak and through our template's email address either as a pre-EUA or a question about whether enrichment can be used for those tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: enrichment methods, bias elimination, test validation
REVIEW FLAG: False


#### 14. Determining Appropriate Comparator for Antigen Test Validation

QA Block 14-1
CLARIFIED QUESTION: Is it acceptable to use RT isothermal amplification as a comparator for a saliva test instead of RT-PCR?
CLARIFIED ANSWER: The FDA recommends reaching out to the designated email to determine the appropriate comparator for your test and study.
VERBATIM QUESTION: Is it acceptable to use RT isothermal amplification as a comparator for a saliva test instead of RT-PCR?
VERBATIM ANSWER: Well, yes, I think if you reach out to the template's email address. We'll work with you on what an appropriate comparator is for your test and your study.
SPEAKER QUESTION: Susan Sheldon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator testing, RT isothermal amplification, FDA consultation
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: What is the appropriate comparator for an antigen lateral flow test?
CLARIFIED ANSWER: FDA recommends using a nasal pharyngeal swab and an EUA-authorized high-sensitivity molecular test as the comparator for antigen lateral flow tests. The test should account for cycle threshold values to assess performance.
VERBATIM QUESTION: What is the appropriate comparator for an antigen lateral flow test?
VERBATIM ANSWER: Yes. For a comparator test and swab for saliva, that doesn't matter whether it's antigen or molecular. We are still recommending a nasal pharyngeal swab. And using a EUA authorized high-sensitivity molecular test. We do look for cycle threshold numbers that are in the lower viral load level to make sure that we know the test performs across the dynamic range. And so you can use a test that doesn't have cycle threshold follow-up. But then we really need to know another test, you know, what the cycle - using another test, what the cycle threshold is. So it's just probably easier to see a comparator test.
SPEAKER QUESTION: Susan Sheldon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: comparator requirements, antigen lateral flow tests, EUA molecular tests
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: What cycle threshold requirements need to be met to confirm performance across the dynamic range of a diagnostic test?
CLARIFIED ANSWER: FDA requires cycle threshold numbers at the lower viral load level to confirm test performance across the dynamic range. If using a test without cycle threshold follow-up, another test's cycle threshold must be determined for verification.
VERBATIM QUESTION: What cycle threshold requirements need to be met to confirm performance across the dynamic range of a diagnostic test?
VERBATIM ANSWER: We do look for cycle threshold numbers that are in the lower viral load level to make sure that we know the test performs across the dynamic range. And so you can use a test that doesn't have cycle threshold follow-up. But then we really need to know another test, you know, what the cycle - using another test, what the cycle threshold is. So it's just probably easier to see a comparator test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: cycle threshold requirements, test performance, dynamic range
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: Can a test without cycle threshold follow-up be used as a comparator if data from another test with cycle threshold information is provided?
CLARIFIED ANSWER: A test without cycle threshold follow-up can be used as a comparator if another test provides the necessary cycle threshold information.
VERBATIM QUESTION: Can a test without cycle threshold follow-up be used as a comparator if data from another test with cycle threshold information is provided?
VERBATIM ANSWER: We do look for cycle threshold numbers that are in the lower viral load level to make sure that we know the test performs across the dynamic range. And so you can use a test that doesn't have cycle threshold follow-up. But then we really need to know another test, you know, what the cycle - using another test, what the cycle threshold is. So it's just probably easier to see a comparator test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: comparator test, cycle threshold, test requirements
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: What is the process for contacting the FDA about appropriate comparators for a diagnostic test?
CLARIFIED ANSWER: Contact the FDA by emailing the template's email address; they will assist in determining an appropriate comparator for your diagnostic test.
VERBATIM QUESTION: What is the process for contacting the FDA about appropriate comparators for a diagnostic test?
VERBATIM ANSWER: Well, yes, I think if you reach out to the template's email address. We'll work with you on what an appropriate comparator is for your test and your study.
SPEAKER QUESTION: Susan Sheldon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: comparator selection, FDA contact process, diagnostic test feedback
REVIEW FLAG: False

QA Block 14-6
CLARIFIED QUESTION: What steps should developers take to confirm the appropriateness of their selected comparator?
CLARIFIED ANSWER: Developers should contact the FDA's template email address to confirm the appropriateness of their comparator. The FDA recommends reaching out to double-check the selected comparator.
VERBATIM QUESTION: What steps should developers take to confirm the appropriateness of their selected comparator?
VERBATIM ANSWER: Okay, all right. Well, yes, I think if you reach out to the template's email address. We'll work with you on what an appropriate comparator is for your test and your study. We actually prefer that developers reach out and just double check the comparator they would use so hopefully that
SPEAKER QUESTION: Susan Sheldon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator selection, Developer guidance, FDA resources
REVIEW FLAG: False

QA Block 14-7
CLARIFIED QUESTION: Is there guidance on where to find the presentation and transcript of today's Town Hall after it concludes?
CLARIFIED ANSWER: The presentation and transcript of today's Town Hall will be available on the CDRH Learn webpage by Friday, May 7.
VERBATIM QUESTION: Is there guidance on where to find the presentation and transcript of today's Town Hall after it concludes?
VERBATIM ANSWER: Today's presentation and transcript will be available on CDRH Learn web page at www.fda.gov/training/cdrhlearn by Friday, May 7. If you have additional questions about today's presentation, please email cdrh-eua- templates@fda.hhs.gov.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Ivory Howard (FDA)
TOPICS: availability of Town Hall materials, FDA resources
REVIEW FLAG: False

### removed qa blocks
QA Block 4-4
CLARIFIED QUESTION: What are the validation requirements for pooled serial screening with anterior nasal swabs?
CLARIFIED ANSWER: Validation requirements for pooled serial screening with anterior nasal swabs are provided in the appendices of the amendment and must be submitted prior to testing. Pooled testing with other specimen types or outside of a Serial Testing Program requires a supplemental EUA request.
VERBATIM QUESTION: What are the validation requirements for pooled serial screening with anterior nasal swabs?
VERBATIM ANSWER: The validation requirements are for that pooled serial screening. The anterior nasal swab is - are laid out in the appendices of the amendment and should be submitted ahead of testing. If a sponsor is interested in offering pooled testing separate from a Serial Testing Program or offering pooled testing with specimen types other than anterior nasal swabs you can submit a supplemental EUA request to your underlying EUA to request those claims.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Validation requirements, Pooled serial screening, Anterior nasal swabs
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 12:33:15 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 14
##### Explicit Questions Extraction
QE 1-1: Does the pooling and serial testing amendment only apply to RT-PCRs or can other types of nucleic acid amplification tests (NAATs) also fall under this amendment?
QE 1-2: Are the validation approaches outlined in the appendices of the amendment applicable to other types of NAATs depending on the technology?

##### Implicit Questions Extraction
QI 1-1: What information about prevalence assumptions is provided on the updated EUA serology test performance webpage?
QI 1-2: How should healthcare providers interpret predictive values on serology tests based on new prevalence data?
QI 1-3: What does Condition F in the recent pooling and serial testing amendment entail regarding post-authorization studies?
QI 1-4: What are the validation submission requirements for the pooling aspect of tests under the new amendment?
QI 1-5: What guidance is provided in the serial screening supplemental template for tests claiming screening prior to validation with asymptomatic individuals?
QI 1-6: What are the paths to authorization for tests that did not previously have screening claims under the new pooling and serial testing amendment?
QI 1-7: Are there specific validation options for tests lacking CT scores in pooling scenarios?

#### Section 2 of 14
##### Explicit Questions Extraction
QE 2-1: Can both analytical and clinical performance testing for the post-authorization study for asymptomatic individuals be provided post-authorization?
QE 2-2: Do amendments to an existing EUA include all instruments that are part of the existing authorization if they are eligible?

##### Implicit Questions Extraction
QI 2-1: What are the eligibility requirements for a test to qualify under the pooling and serial testing amendment?
QI 2-2: Why are tests validated with contrived specimens or with a PPA below 95% excluded from the pooling and serial testing amendment?
QI 2-3: Are tests without multiple targets on the SARS-CoV-2 genome or not classified as multi-analyte automatically ineligible for the pooling and serial testing amendment?
QI 2-4: If a test meets the criteria for the pooling and serial testing amendment, how are multiple instruments included in the test configuration processed under the amendment?

#### Section 3 of 14
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 3-1: What are the specific metrics required for validation under the amendment?
QI 3-2: What process should an EUA holder follow to submit validation data for a specific indication?
QI 3-3: Are there any validation exemptions for pooling procedures when pools are up to and equal to an N of 3?
QI 3-4: What details must be included in the validation submission to add a test to the exhibit of the amendment?
QI 3-5: What updated labeling requirements are necessary for submission under the amendment?
QI 3-6: What are the expectations for pooling procedures to comply with the amendment?

#### Section 4 of 14
##### Explicit Questions Extraction
QE 4-1: Is pooling without preauthorization from FDA limited to pools of three?
QE 4-2: Does the pooling and serial testing amendment apply to different specimen types including saliva or is it limited to anterior nasal swab specimens?
QE 4-3: Does testing pooled specimens outside of Serial Testing Programs fall under the pooling and serial testing amendment?
QE 4-4: What are the validation requirements for pooled serial screening with anterior nasal swabs?
QE 4-5: How can a sponsor offer pooled testing outside of a Serial Testing Program or use specimen types other than anterior nasal swabs?
QE 4-6: What validation approaches can be considered for pooling anterior nasal swabs separate from a Serial Testing Program?
QE 4-7: Has the FDA authorized saliva pooling for testing under these amendments?
QE 4-8: What should sponsors do if they have alternate approaches for validation they wish to discuss?

##### Implicit Questions Extraction
QI 4-1: What is the process for submitting a request under the pooling and serial testing amendment?
QI 4-2: What specific information needs to be included in a supplemental EUA request for pooled testing outside of a Serial Testing Program?
QI 4-3: What are the FDA's expectations for data validation when pooling saliva specimens, despite saliva pooling not being authorized?
QI 4-4: Are there specific reasons the FDA has observed poor performance data for saliva pooling, and should alternate specimen types be considered instead?
QI 4-5: What should be included in a pre-EUA submission when proposing alternate approaches for validation?
QI 4-6: What are the detailed validation requirements for anterior nasal swabs as outlined in the appendices of the amendment?

#### Section 5 of 14
##### Explicit Questions Extraction
QE 5-1: Is physician authorization required for the pooling and serial testing amendment?
QE 5-2: Could CMS do anything about making a CLIA Waiver not required?

##### Implicit Questions Extraction
QI 5-1: Does the pooling and serial testing amendment impact the prescription status of EUA tests?
QI 5-2: When is a CLIA certificate required for facilities performing COVID-19 tests?
QI 5-3: Does self-testing with home-use authorized tests require a CLIA certificate?

#### Section 6 of 14
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 6-1: What is the process for monitoring the impact of viral mutations on COVID-19 tests?
QI 6-2: How frequently is the SARS-CoV-2 viral mutations web page updated?
QI 6-3: What criteria would trigger updates or changes to rapid test sensitivity assessments?

#### Section 7 of 14
##### Explicit Questions Extraction
QE 7-1: Can banked samples be used to supplement if 30 symptomatic positive samples are not achieved after 2 weeks of enrollment?
QE 7-2: Should negative banked samples also be tested?
QE 7-3: Do banked samples need to come from symptomatic subjects, or can they come from any positive or negative samples?
QE 7-4: If banked samples are used to supplement, do they need to be the same sample type as what is claimed in the IFU?
QE 7-5: If the sample type claimed is direct samples with no transport media but the banked samples are in transport media, is that acceptable?

##### Implicit Questions Extraction

#### Section 8 of 14
##### Explicit Questions Extraction
QE 8-1: What does FDA expect to see regarding precision and reproducibility studies for a 510(k) submission for a molecular SARS-CoV-2 test?
QE 8-2: Can the manufacturer site be one of the three sites for reproducibility studies in a 510(k) submission for a molecular SARS-CoV-2 test?
QE 8-3: Can an EUA-authorized high-sensitivity RT-PCR assay be used as the comparator instead of BioFire in clinical studies for a 510(k) submission?
QE 8-4: Does FDA suggest submitting a pre-submission for proposed validation strategies and comparator methods when pursuing a 510(k) for a molecular SARS-CoV-2 test?

##### Implicit Questions Extraction
QI 8-1: What criteria must be met for a manufacturer site to qualify as one of the study sites in a reproducibility study?
QI 8-2: Are there specific guidelines for evaluating reproducibility across different operators at each site?

#### Section 9 of 14
##### Explicit Questions Extraction
QE 9-1: Is it realistic to think that FDA may adopt practices similar to the UK and Germany to increase the availability of antigen tests?
QE 9-2: Would FDA be amendable to accepting studies from an institute like Karolinska in Sweden for analytical validation?
QE 9-3: Does it make sense to use a high-performance RT-PCR test with CT values as a comparator instead of tests like Abbott BinaxNOW or QuickVue?

##### Implicit Questions Extraction
QI 9-1: What are the alternative testing approaches if a BSL-3 lab is unavailable?
QI 9-2: Are inactivated viruses (e.g., heat or radiated) acceptable for analytical studies, and how should they be used?
QI 9-3: Can diluted clinical samples be utilized for FDA-required analytical studies, and are there specific guidelines for such use?
QI 9-4: Does the FDA routinely consult with international organizations or use data from countries like the UK and Germany in their decision-making process?
QI 9-5: What criteria does the FDA require to establish 'truth' in comparator tests for antigen tests?
QI 9-6: Are there flexibility options for modifying study designs if tests perform well in extended symptomatic periods?
QI 9-7: Does the FDA have any influence or involvement in the pricing of commercial COVID-19 tests?

#### Section 10 of 14
##### Explicit Questions Extraction
QE 10-1: Can you please repeat and explain what you mentioned about the serology testing from 5% to 50%?

##### Implicit Questions Extraction
QI 10-1: What additional data is available on the EUA authorized serology test performance regarding prevalence assumptions between 5% and 50%?
QI 10-2: Why is it important to validate antigen test sensitivity with low positive specimens in addition to high positive specimens?
QI 10-3: What does the FDA consider an appropriate use of antigen test results, given that they are presumptive negatives?
QI 10-4: Why should antigen test results below 95% sensitivity not be used for isolation or social distancing decisions?
QI 10-5: What is the FDA's stance on the necessity of serial testing for asymptomatic individual identification across all test types?
QI 10-6: What are the labeling language requirements for rapid point-of-care and home lateral flow antigen tests that have lower sensitivity than central lab molecular tests?
QI 10-7: What constitutes appropriate clinical management in cases where antigen test results need molecular assay confirmation?

#### Section 11 of 14
##### Explicit Questions Extraction
QE 11-1: Would the FDA expect to see usability testing with Chinese-speaking users if a manufacturer intends to provide instructions in English and Chinese in one combined digital IFU?
QE 11-2: Does the assumption that separate documents may not require Spanish-speaking users in usability testing change the thought process if the instructions are combined or separated?
QE 11-3: How can one enrich a population to accumulate asymptomatic positives for breath test development?

##### Implicit Questions Extraction
QI 11-1: What are the FDA's current recommendations for usability testing of digital instructions for use in languages other than English and Spanish?
QI 11-2: Would the FDA consider updating their template to provide more flexibility for combined or multi-language instructions?
QI 11-3: What are the specific requirements for listing a new Class 1 exempt extraction kit under the JJH Pro Code?
QI 11-4: What steps should a developer take to collaborate with assay developers to validate a new extraction kit?
QI 11-5: How can a test developer request the FDA's current thinking or draft guidelines for breath test development?
QI 11-6: What is the recommended number of positive and negative samples for validation studies in breath test devices?
QI 11-7: What key considerations should be included in a pre-EUA submission for breath test development?

#### Section 12 of 14
##### Explicit Questions Extraction
QE 12-1: Will there be any clinical utility for a companion diagnostic test to identify the KLA variant or specific mutations involved with a positive specimen?
QE 12-2: Should we go through the pre-submission process with the templates since we have a full set of analytical and clinical evaluations for all known variants?
QE 12-3: What is FDA's position on a finger stick point of care serology test that uses a full S1 protein antigen and if all performance and criteria in the serology template are included, would this address FDA's concerns on current variants?

##### Implicit Questions Extraction
QI 12-1: What are the FDA's current recommendations for validating sequencing or genotyping tests intended to report mutation or variant information?
QI 12-2: Under what circumstances will the FDA not regulate the genotyping or sequencing component of a SARS-CoV-2 detection test?
QI 12-3: What labeling requirements must be met to ensure genotyping or variant information is not transmitted to patients without FDA authorization?
QI 12-4: Can developers submit data or publications directly to the FDA for review and how should they do this?
QI 12-5: Is it advisable to submit a pre-EUA for feedback on studies not yet initiated?
QI 12-6: What steps should a developer follow if they have completed all analytical and clinical evaluations and are ready to submit for EUA authorization?
QI 12-7: What is the FDA's position on the inability to compare quantitative values between different antigen tests due to the lack of fully quantitative antigen tests or reference material?
QI 12-8: What plans for ongoing monitoring of mutations and variants should be included in an EUA request for a serology test?

#### Section 13 of 14
##### Explicit Questions Extraction
QE 13-1: Would it be acceptable to add to the validation test subjects from out of the U.S. for an asymptomatic claim?
QE 13-2: Is it correct that with 2% prevalence and the requirement for 100 positive asymptomatic cases, approximately 50,000 test subjects would be needed?

##### Implicit Questions Extraction
QI 13-1: What additional validation steps are required for the authorization of a breath-based test for respiratory disease?
QI 13-2: Can developers use enrichment processes, such as linking with serial testing programs, to meet sample requirements for asymptomatic positive cases?
QI 13-3: How does the intended setting for the test's use (e.g., at-home, point-of-care, or laboratory) affect the study design and validation requirements?
QI 13-4: Are there specific considerations for demonstrating the performance of breath tests in moderately or highly complex lab settings?
QI 13-5: What are the FDA's expectations for eliminating bias when employing enrichment methods in test validation studies?

#### Section 14 of 14
##### Explicit Questions Extraction
QE 14-1: Is it acceptable to use RT isothermal amplification as a comparator for a saliva test instead of RT-PCR?
QE 14-2: What is the appropriate comparator for an antigen lateral flow test?

##### Implicit Questions Extraction
QI 14-1: What cycle threshold requirements need to be met to confirm performance across the dynamic range of a diagnostic test?
QI 14-2: Can a test without cycle threshold follow-up be used as a comparator if data from another test with cycle threshold information is provided?
QI 14-3: What is the process for contacting the FDA about appropriate comparators for a diagnostic test?
QI 14-4: What steps should developers take to confirm the appropriateness of their selected comparator?
QI 14-5: Is there guidance on where to find the presentation and transcript of today's Town Hall after it concludes?
